Genetic analysis of chromosomal regions 2q33, 7q32 and 19q13 in multiple sclerosis susceptibility by Bonetti, Alessandro
 
 
1
Helsinki Biomedical Graduate School 
University of Helsinki, Finland 
 
 
 
Helsinki University Biomedical Dissertations No. 130 
 
 
Genetic analysis of chromosomal regions 2q33, 7q32 
and 19q13 in multiple sclerosis susceptibility 
 
Alessandro Bonetti 
Research Program of Molecular Neurology, Biomedicum Helsinki 
and 
Department of Neurosciences, Institute of Clinical Medicine 
University of Helsinki, Finland 
 
 
 
ACADEMIC DISSERTATION 
 
To be publicly discussed 
with the permission of the Faculty of Medicine of the University of  
Helsinki, for public examination in Biomedicum Helsinki, Lecture Hall 2, 
on October 30th, 2009, at 12h00 
 
Helsinki 2009  
 
 
2
Supervised by 
Docent (adjunct professor) Pentti Tienari MD PhD 
Research Program of Molecular Neurology, Biomedicum Helsinki 
University of Helsinki 
and  
Helsinki University Central Hospital, Department of Neurology 
Finland 
 
Reviewed by 
Docent (adjunct professor) Jukka Partanen PhD 
Finnish Red Cross Blood Service 
Helsinki, Finland 
 
and  
 
Assistant professor Tomi Pastinen MD PhD 
Departments of Human Genetics and Medical Genetics 
McGill University and Genome Quebec Innovation Centre 
Montreal, Canada 
 
Discussed by 
Docent (adjunct professor) Päivi Saavalainen PhD 
Department of Medical Genetics 
University of Helsinki 
Finland 
 
 
 
ISBN 978-952-10-5828-8 (paperback), ISBN 978-952-10-5829-5 (PDF) 
ISSN 1457-8433 
 
Helsinki University Print 
Helsinki 2009 
 
 
3
ACKNOWLEDGEMENTS 
 
The  work  described  in  this  thesis  was  carried  out  in  the  laboratory  of  Pentti  Tienari  at  the  
Research Program of Molecular Neurology (formerly Neurosciences) in Biomedicum Helsinki 
between April 2003 and July 2009. 
 
My acknowledgements start obviously from my supervisor Pentti Tienari. I deeply thank him for 
the resources and the help he provided, the discussions we engaged about science and subjects 
concerning  other  aspects  of  human activities.  I  thank  my coauthors  for  their  collaboration  and  
interest. I am deeply grateful to the external reviewers of this thesis, adjunct prof. Jukka Partanen 
and assistant prof. Tomi Pastinen, for their availability, feedback and extremely quick response. 
I  wish  to  express  my gratitude  and  honor  to  adjunct  prof.  Päivi  Saavalainen  for  accepting  the  
post of opponent. My warm thanks to Prof. Anu Wartiovaara for accepting the kustos role and 
for “adopting” me in her group during the journal club series. I would like to express my 
heartfelt gratitude Dr. Brendan Battersby for the language review, the constant support he 
provided me with endless scientific questions and most importantly for being a real friend. I am 
grateful to Prof. Juha Kere for being a member of thesis committee and for his valuable 
comments and advices.  
 
Helsinki Biomedical Graduate School is thanked for supporting my salary during four years. The 
Center for International Mobility, Emil Aaltonen Foundation, Sigfrid Juselius Foundation, 
Academy of Finland and Finnish Cultural Foundation are thanked for providing funds during the 
years. 
 
A special “grazie” goes to Lilja Jansson for the help, the pain and the laugh shared during these 
six years: even when everything seemed to not work we were able to have genuine fun. And I 
cannot forget Hannele Pihlaja for the help given in the first part of my life spent in PT lab. KP 
for entertaining my working days with socio-cultural trivia and for sharing interesting scientific 
ideas, Terhi R-H for helping me out through the analysis of genetic results in the beginning of 
my PhD studies. 
 
Now comes the difficult part. Being a social person exposes me to a plethora of individuals 
during and after my working hours. Every person crossing my path during these years has played 
a somewhat important role but it is practically impossible to mention everybody. Tatiana, you 
 
 
4
brought in the last part of my studies a lot of energy and fun. Nuno and Zuzana, our discussion 
about science and most importantly life have not vanished from my memories; Iulia, Joao, 
Karen, Maurice and especially Vincenzo, you entertained my working hours with good laughs 
and more serious stuff. To all the past and present members of AW, BB and Iiris Hovatta labs, 
thanks for tolerating my noisy presence throughout these years. To all the neurobastards (among 
which Annamari, Antti “the man”, Jana, Kati, Riikka, Sofia and Valtteri deserve special 
mention) that have been hanging out with me during the cold winter nights and the warm 
summer evenings, celebrating life has been pure enjoyment. I want to thank Anu H, Markus and 
Tuula for the expertise and help in every day working life, Joni and Chris for putting up with me 
in good and bad times, Anna H and Eino for sharing intriguing thoughts about the functioning of 
human body and especially Ilse and Paula for being true friends. To my past and present volley 
mates for enjoying victories and washing losses away with an adequate amount of ethanol, to my 
football team-mates (Dario, Ettore, Giulio, Massimo, Rosario, Simone) for unnecessarily spicing 
my summers up. 
 
I still remember as if it was yesterday the moment I joined the lab of Prof. Tommaso Russo in 
Napoli. It was September 1998 and I was a young student full of hopes and dreams. I’m deeply 
indebted to him for guiding me through my master degree studies. It is still very clear in my 
memory  the  words  he  used  to  describe  the  “mission”  of  the  scientist:  we  do  this  job  because  
there’s a sacred fire burning in our chest. After eleven years that flame has not been extinguished 
yet. I cannot forget Dr. Giuseppina “Giusy” Minopoli, a fundamental person in my three years 
spent  at  the  Department  of  Biochemistry  and  Molecular  Biology.  Then  it’s  the  turn  of  my  
colleagues around the world, a proof of what our beloved country, Italy, has obliged us to do for 
finding proper personal scientific reward and dignity elsewhere: Karlo, Tapete, Tieghe, Elena, 
(viol)Enza, Eva, Luca, Mariah and Marsilio. The memories of those amazing years will never be 
forgotten. 
 
I guess it’s time to wrap it up and finish by thanking my family. To my parents Gennaro and 
Marilena and to my sister Laura for supporting continuously me and my not-so-orthodox 
choices. All this rambling cannot be concluded without mentioning Mia, the person that has 
witnessed hopes and frustrations throughout these years.  
 
Alessandro Bonetti 
Helsinki, September 24th 2009 
 
 
5
“Fatti non foste a viver come bruti ma per seguir virtute e canoscenza”  
Your fate is not to rummage in the mud, yet to progress in moral value and knowledge 
 
Dante Alighieri, Divina Commedia, Inferno canto XXVI 116-20 
 
 
 
Life is what happens to you while you’re busy making other plans 
 
John Lennon in Beautiful Boy 
 
 
 
Destroy the altar whose boundaries tides will never exceed,  
ignite the pyres underneath a sedated mythology 
 
Circle Takes The Square in In The Nervous Light of Sunday 
 
 
 
And I knew the echo that is love 
and I knew the secrets in your spires 
and I knew the emptiness of youth 
and I knew the solitude of heart 
and I knew the murmurs of the soul 
 
Billy Corgan in Muzzle 
 
 
 
The definition of stupidity is doing the same thing  
over and over again and expecting different results 
 
Albert Einstein 
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ABSTRACT 
 
Multiple sclerosis (MS) is an immune-mediated demyelinating disorder of the central nervous 
system (CNS) affecting 0.1-0.2% of Northern European descent population. MS is considered to 
be a multifactorial disease, both environment and genetics play a role in its pathogenesis. 
Despite several decades of intense research, the etiological and pathogenic mechanisms 
underlying MS remain still largely unknown and no curative treatment exists. 
 
The genetic architecture underlying MS is complex with multiple genes involved. The strongest 
and the best characterized predisposing genetic factors for MS are located, as in other immune-
mediated diseases, in the major histocompatibility complex (MHC) on chromosome 6. In 
humans MHC is called human leukocyte antigen (HLA).  Alleles  of  the  HLA locus have been 
found to associate strongly with MS and remained for many years the only consistently 
replicable genetic associations. However, recently other genes located outside the MHC region 
have been proposed as strong candidates for susceptibility to MS in several studies. 
 
In this thesis a new genetic locus located on chromosome 7q32, interferon regulatory factor 5 
(IRF5), was identified in the susceptibility to MS. In particular, we found that common variation 
of the gene was associated with the disease in three different populations, Spanish, Swedish and 
Finnish. We also suggested a possible functional role for one of the risk alleles with impact on 
the expression of the IRF5 locus.  
 
Previous studies have pointed out a possible role played by chromosome 2q33 in the 
susceptibility to MS and other autoimmune disorders. The work described here also investigated 
the involvement of this chromosomal region in MS predisposition. After the detection of genetic 
association with 2q33 (article-1), we extended our analysis through fine-scale single nucleotide 
polymorphism (SNP) mapping to define further the contribution of this genomic area to disease 
pathogenesis (article-4). We found a trend (p=0.04) for association to MS with an intronic SNP 
located in the inducible T-cell co-stimulator (ICOS) gene, an important player in the co-
stimulatory pathway of the immune system. Expression analysis of ICOS revealed a novel, 
previously uncharacterized, alternatively spliced isoform, lacking the extracellular domain that is 
needed for ligand binding. The stability of the newly-identified transcript variant and its 
subcellular localization were analyzed. These studies indicated that the novel isoform is stable 
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and shows different subcellular localization as compared to full-length ICOS. The novel isoform 
might have a regulatory function, but further studies are required to elucidate its function.  
 
Chromosome 19q13 has been previously suggested as one of the genomic areas involved in MS 
predisposition. In several populations, suggestive linkage signals between MS predisposition and 
19q13 have been obtained. Here, we analysed the role of allelic variation in 19q13 by family 
based association analysis in 782 MS families collected from Finland. In this dataset, we were 
not able to detect any statistically significant associations, although several previously suggested 
markers were included to the analysis. Replication of the previous findings on the basis of 
linkage disequilibrium between marker allele and disease/risk allele appears notoriously difficult 
because of limitations such as allelic heterogeneity. Re-sequencing based approaches may be 
required for elucidating the role of chromosome 19q13 with MS. 
 
This thesis has resulted in the identification of a new MS susceptibility locus (IRF5) previously 
associated with other inflammatory or autoimmune disorders, such as SLE. IRF5 is one of the 
mediators of interferons biological function. In addition to providing new insight in the possible 
pathogenetic pathway of the disease, this finding suggests that there might be common 
mechanisms between different immune-mediated disorders. Furthermore the work presented 
here has uncovered a novel isoform of ICOS, which may play a role in regulatory mechanisms 
of ICOS, an important mediator of lymphocyte activation. Further work is required to uncover 
its functions and possible involvement of the ICOS locus in MS susceptibility. 
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INTRODUCTION  
 
Multiple sclerosis (MS) is a chronic, demyelinating condition of the central nervous system with 
putative autoimmune pathogenesis and unknown etiology. With a prevalence of about 1 in 1000 
individuals of Northern European descent, MS is the most common disorder of neurological 
disability in young adults. The disease has a highly variable clinical course. Both environmental 
and genetic factors are thought to be involved in its pathogenesis. Although it has been 
intensively studied in the last decades, the molecular mechanisms underlying MS are still largely 
unknown. 
 
The complex nature of MS complicates the study of individual genes and their contribution in 
the disease process. However, in recent years molecular genetic tools have provided scientists 
with new means for identifying genetic factors involved in susceptibility to complex disorders. 
The aim of this thesis work was to dissect other possible MS predisposing loci by integrating 
both genetic and molecular biology approaches. Recently it has become evident that the genetic 
mapping of common disorders greatly benefits from the integration of different methods and 
techniques. 
 
Previous studies performed in several populations have pointed out a possible role played by 
2q33 and 19q13 chromosomal regions in the predisposition to MS and other autoimmune 
disorders. Interferon response factor-5 (IRF5) gene was analysed based on previous evidence 
suggesting that allelic variation of IRF5 contributes to the archetypal autoimmune disease, 
systemic lupus. In this thesis we tested whether these loci would be involved in the genetic 
predisposition of MS. A better understanding of MS susceptibility might shed new light into the 
pathogenesis and treatment of the disease and even provide new tools to identify individuals at 
higher risk for possible preventive strategies. 
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REVIEW OF THE LITERATURE 
 
1. MULTIPLE SCLEROSIS 
 
1.1 CLINICAL ASPECTS 
Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system (CNS) 
resulting in loss of myelin sheath (demyelination) and axonal damage. It typically begins 
between  the  ages  of  20  and  40  and  manifests  with  different  clinical  symptoms.  It  can  be  
clinically categorized as either relapsing-remitting MS (RRMS, observed in 85-90% of patients) 
or primary progressive MS (PPMS). Despite intense research the etiology remains unknown, the 
pathogenesis is still unclear and at the moment no curative treatment is available. 
 
The credit for the clinico-pathological characterization of MS belongs the French pathologist 
Jean-Martin Charcot in 1868. He coined the term “multiple sclerosis” (in French “sclèrose en 
plaques”) referring to the scars (scleroses, also known as plaques or lesions) in the white matter 
of patients’ brain and spinal cord. 
 
MS is slightly more common in females than in males with a female:male ratio of approximately 
2:1. MS symptoms normally occur in episodic acute periods of worsening (relapses), in the 
gradually progressive loss of neurological functions, sometimes in combination of both. MS 
patients can suffer from a wide spectrum of neurological symptoms. The initial signs vary 
greatly between patients and even from one attack to another in the same person. The most 
common symptoms are changes in sensation (numbness and paresthesiae), impaired vision, 
difficulties with coordination and balance (ataxia), pareses, fatigue and incontinence.  
 
MS can be difficult to diagnose since its symptoms and signs may overlap with other medical 
conditions. As there is no specific single laboratory test, the diagnosis of MS is mostly done by 
combining clinical and “paraclinical” information, such as magnetic resonance imaging (MRI) 
and analysis of the cerebrospinal fluid (CSF). This has lead to the establishment of diagnostic 
criteria for the needs of clinicians. Historically Schumacher’s criteria (1965) have initially been 
applied in clinical practice and later replaced by the newer guidelines suggested by Poser and 
colleagues  (1983)  with  different  degrees  of  diagnostic  certainty  (clinically  possible  MS,  
clinically probable MS, laboratory-supported definite MS, and finally the most certain diagnostic 
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level clinically definite MS). More recently other criteria combining clinical, laboratory and 
especially MRI data have been introduced to facilitate the early diagnosis of MS in patients who 
presents symptoms that might be suggestive of the disease (McDonald et al 2001). 
 
1.2 BASIC FEATURES OF THE MS LESIONS 
One of the hallmarks of MS is the presence of large, multifocal, sharp-edged, demyelinated 
plaques with reactive glial scar formation (Compston et al 2006). These characteristic lesions are 
accompanied by the infiltration of inflammatory mediators, mainly T-cells and macrophages. 
Active lesions, defined by the ongoing destruction of myelin, are populated by macrophages and 
activated microglial cells, whereas in advanced inactive plaques the centre of the lesion is 
characterized by gliotic astrocytic fibers. Although myelin sheaths are the primary target of the 
inflammatory process, the axons beneath the myelin, cortical neurons and astrocytes are also 
affected. In fact demyelination can be partially repaired by remyelination but axonal destruction 
is irreversible and responsible for the accumulation of the neurological deficits. 
 
Lucchinetti et al (2000) analyzed the pathology of archival material consisting of 51 biopsies and 
32 autopsies "with histologically proven active MS". Four different patterns of demyelination 
were found using immunological and neurological markers (Table 1). 
 
The analysis of Lucchinetti et al (2000) revealed heterogeneity in patterns of demyelination 
between different patients, whereas multiple active lesions from the same patient were very 
similar.  In the first  pattern,  demyelination is induced by the release of cytokines,  enzymes and 
reactive oxygen intermediates from activated macrophages. The second pattern is caused by 
myelin-reactive antibodies and activated complement. In the third pattern white matter ischemia 
or viral infection induces apoptosis of oligodendrocytes. The last pattern is caused by deficiency 
in oligodendrocytes metabolism and a subsequent higher vulnerability to the toxic action of 
inflammatory mediators. All these patterns may result in axonal injury that follows the acute 
destruction of myelin sheaths with permanent neurological dysfunction. It should be noted that 
many of the samples were biopsies taken for diagnostic purpose. Biopsy, per se, is an indication 
of atypical features of demyelinating disease, biopsy is not typically used in the normal 
diagnostic work-up of MS. Therefore, this study has been criticized for the possible inclusion of 
non-MS cases, especially disseminated encephalomyelitis cases (Poser 2000). 
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PATTERNS OF 
DEMYELINATION 
PATHOLOGY PUTATIVE MECHANISMS 
(I) Macrophage 
mediated 
 
 
Inflammatory infiltrates composed 
of T-cells and macrophages; 
activated macrophages and 
microglia. Signs of remyelination. 
T-cell mediated activation of 
macrophages and microglia, 
which secret meylinotoxic 
substances. 
(II) Antibody mediated Similar lesions as in (I) with 
additional deposition of antibodies 
and activated complement. Signs of 
remyelination. 
T- and B-cell mediated 
inflammation with 
demyelination mediated by 
antibody-targeted complement. 
(III) Distal 
oligodendropathy 
Inflammatory infiltrates composed 
of T-cells and macrophages with 
small vessel vasculitis and 
degenerating apoptotic 
oligodendrocytes. 
T-cell mediated vasculitis with 
secondary ischemic damage of 
the white matter. 
(IV) Primary 
oligodendrocyte 
damage with secondary 
demyelination 
Similar lesions as in (I) with 
prominent oligodendrocyte 
degeneration, no remyelination.  
Oligodendrocytes are 
metabolically impaired. 
Secondary T-cell mediated 
inflammation with activation of 
macrophage and microglia.  
Table 1. Different patterns of demyelination in active MS plaques observed in the series of 
Lucchinetti et al (2000). 
 
 
In  another  study  of  39  patients,  diagnosed  (antemortem)  as  clinically  definite  MS  and  
subsequently neuropathologically analysed, similar heterogeneity of MS lesions was not found 
(Breij et al, 2008). In these subjects the dominant pattern of active demyelination was similar to 
the type II pattern above. Active complement, immunoglobulin G (IgG) and activated 
macrophages/microglia were consistently found. Signs of ischemia (type III) or oligodendrocyte 
apoptosis (type III and IV) were not found. Hence, it is still debatable, whether all four patterns 
of demyelination occur in MS. 
 
1.3 DIAGNOSTIC LABORATORY TESTS 
MS patients are characterized by the occurrence of several immunological abnormalities 
involving  both  humoral  and  cell-mediated  immune  systems.  One  of  the  laboratory  parameters  
that best correlates with MS is the presence of oligoclonal bands (OBs). OBs are clusters of 
immunoglobulins that are detected from CSF and serum with the help of isoelectric focusing. 
Visually OBs appear as discrete bands that stand out from the background in the gel.  OBs 
present  in  the  CSF,  but  not  in  the  serum,  indicate  the  presence  of  antibody  producing  plasma  
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cells in the CNS. CSF specific OBs are found in 90% MS patients. However, such Obs are found 
in other conditions as well (e.g. neurosarcoidosis, neuroborreliosis, stiff-person syndrome, 
chronic meningitis). Another measure of immunoactivation is the increased CSF/serum IgG ratio 
(IgG-index) that  indicates increased overall production of antibodies within the CNS. In terms 
of banding patterns, post-mortem samples  from  the  CNS  of  an  MS  patient  have  revealed  that  
distinct OB-patterns are found in individual plaques, a finding in contrast to the notion of an 
immune reaction against a common epitope (Mattson et al 1990).  
 
So far no clear picture has emerged from the analysis of the specificity of the OBs. Quite 
commonly IgG recognizing common viruses such as measles and varicella are found but these 
antibodies constitute only a minor fraction of OBs. Cortese and co-workers (1996) have utilized 
a strategy based on phage-displayed random peptide libraries to identify ligands for OBs from 
MS patients. The purified epitopes were recognized with equal frequency by the sera of normal 
individuals  and  MS  patients.  Furthermore  the  repertoire  of  CSF  antibodies  appeared  to  be  
individual-specific, suggesting a nonspecific immunedysregulative phenomenon rather than the 
result of an immune reaction towards a common antigen. 
 
Magnetic resonance imaging (MRI) is very sensitive for detecting lesions in the brains of MS 
patients. In MRI using T2-weighted and FLAIR sequences MS plaques appear as brighter areas 
surrounded by normal-appearing white matter which looks darker; the rationale for this is the 
increased water content of the lesions which may be secondary to inflammation or gliosis 
(Figure 1).  
 
For detection of very young lesions paramagnetic substances such as gadolinium can be used to 
demonstrate blood-brain barrier (BBB) leakage. The extent of the plaques as visualized with 
MRI  does  not  always  correlate  with  the  clinical  picture  of  the  patient.  Many  plaques  are  
clinically silent. Even large lesions may be symptomless, while a small plaques in a critical 
anatomical site (e.g. brain stem, spinal cord) may have a strong impact on the neurological 
functions.  Also in the case of MRI diagnostics the lesions are not 100% specific for MS, with 
other conditions (e.g. cerebral vasculitis, sarcoidosis) having sometimes a similar pattern (Miller 
et al 1988). The MRI criteria by Barkhof et al (1997) are recommended in the contemporary 
McDondald's criteria of MS. These MRI criteria pay special attention to the anatomical 
dissemination of lesions. They were originally designed for the prediction of future MS in 
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patients with first clinical symptom suggesting demyelinative disease (so called clinically 
isolated syndrome). 
 
   A                                                                              B 
 
 
 
 
                                                                          
 
 
 
Figure 1. A. Typical sharp-edged leukocyte extravasation around a small calibre vein. B.  MRI 
scans of brains of MS patients (FLAIR sequence) showing multiple periventricular and 
juxtracortical  plaques.  Many  of  the  early  plaques  are  composed  of  the  infiltrating  perivenular  
leukocytes indicated by arrows (Pictures from Pentti Tienari, University of Helsinki). 
 
 
 
 
1.4 THERAPY 
Relapses are often treated with high-dose corticosteroids for a few days. This treatment speeds 
up patients' recovery from the relapse but it is presumed that treatment of corticosteroids at 
relapses does not have impact on the long-term prognosis. Several drugs have been developed to 
improve long-term prognosis of MS. Current MS therapies are immunomodulatory strategies to 
partially protect against relapses and MRI burden, but their effect on long-term prognosis is still 
somewhat unclear. These drugs are ineffective against purely progressive forms of MS. The 
inflammatory nature of MS has been instrumental in leading to the drug treatments presently 
used, but the lack of a detailed understanding of the disease’s pathophysiology has prevented the 
design of more effective therapies. Currently two classes of immunomodulating first-line 
strategies are used to impact the early course of MS: ?-interferons (IFN-?s) and glatiramer 
acetate.  
 
The  rationale  for  using  beta-interferon  (IFN-?)  in  MS  came  partly  from  a  treatment  trial  with  
gamma-interferon (IFN-?), which dramatically increased the relapse-rate of MS patients (Panitch 
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et al, 1987) (the trial was discontinued).  Since IFN-? is partially antagonising the effects of 
IFN-?, it turned out to be a natural candidate for MS treatment. IFN-? is an anti-inflammatory 
regulatory cytokine with antiviral, antineoplastic and immunomodulatory effects. It decreases 
cell migration into CNS, inhibits T-cells proliferation and expression of cell activation markers 
and increases the synthesis of the anti-inflammatory cytokine interleukin 10 (IL-10) and nerve 
growth factor, possibly inducing remyelination and axonal repair (Rudick 1999). The results of 
different clinical trials with RRMS patients have shown a beneficial effect of IFN-? for the 
attack rates and disease activity measured clinically or by MRI (The IFNB study group 1995, 
Rudick  et  al  1997),  whereas  for  the  treatment  of  PPMS  patients  IFN-? has  shown  to  be  not  
effective (Miller et al 2007).  
 
The alternate drug in first-line treatment is the use of glatiramer acetate (GA), a synthetic peptide 
that mimics the epitopes of  myelin basic protein (MBP) and other myelin proteins. GA is a 
random polymer of the four amino acids Glutamate, Lysine,  Alanine and Tyrosine (hence the 
name GLATiramer).  The  rationale  for  using  GA  in  MS  therapy  stems  from  the  idea  that  
autoimmunity against myelin protein, especially MBP, plays an essential role in MS 
pathogenesis (Lisak et al., 1977). GA is designed to act as a decoy for MBP, diverting the 
inflammatory  response  against  myelin.  Recently  it  has  been  shown  that  GA  increases  the  
circulating  levels  of  the  secreted  form of  IL-1  receptor  antagonist  and  therefore  triggers  a  less  
inflammatory profile (Burger et al 2009). In clinical trials GA has been shown to be as effective 
as ? interferon to reduce the number and severity of exacerbations in RRMS (Mikol et al 2008) 
but failed to demonstrate a treatment effect in PPMS (Wolinsky et al 2007).  
Natalizumab is indicated for patients with very aggressive relapsing-remitting MS, who do not 
respond to IFN-? or GA. In the pivotal clinical trial it showed the strongest drug effect thus far 
obtained in reducing relapse rate and MRI activity (Polman et al. 2006). The rationale is to 
prevent circulating leukocytes from migrating to the CNS. Natalizumab is a humanized 
monoclonal antibody directed against the ???1 integrin very late antigen 4 (VLA-4). VLA-4 is 
expressed particularly on T-cells where it has a crucial role in the BBB transmigration 
(Ransohoff 2007): the blockade of VLA-4 inhibits the entrance of immune cells in the CNS and 
ameliorates the disease course. After a successful Phase III study, two cases of progressive 
multifocal leukencephalopathy (PML) occurred with the subsequent withdrawal of the drug 
from the market (Langer-Gould et al 2005, Kleinschmidt-DeMasters et al 2005). A probable 
explanation for the occurrence of PML is CNS immunodeficiency, because of reduced levels of 
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T- and B-cells in the CSF of natalizumab-treated patients (Stuve et al 2006), highlighting the 
complex network of regulation involved in the pathophysiology of MS. 
Immunosuppressive drugs are considered as second-line strategy. Mitoxantrone interferes with 
DNA  synthesis  and  repair,  suppressing  a  variety  of  cells  of  the  immune  system.  The  major  
drawbacks about the long-term treatment with mitoxantrone are its cardiotoxicity and a small 
risk of developing leukaemia, limiting thus the use of such drugs only for a few years. 
Mitoxantrone appears to reduce the number of relapses and burden of disease on MRI (Neuhaus 
et al, 2007). Azathioprine, a purine analogue, is a less potent immunosupressant that has also 
been shown to reduce relapses in meta-analysis (Yudkin et al., 1991) but since it is an old drug 
large-scale modern trials have not been conducted. 
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2. EPIDEMIOLOGY 
 
2.1 INCIDENCE AND PREVALENCE 
MS has an uneven geographical distribution which is seen on a regional and world scale. The 
cause for such peculiar distribution has been debated for long time, invoking both genetic and 
environmental factors. Genetic predisposition cannot explain alone the remarkable differences 
observed in the geographical variations but the search for putative environmental culprits has not 
produced definitive results. The current view is that, although there might be independent 
additive risk factors, susceptibility is mediated by direct interactions between the environment 
and genes. 
 
MS is rare in Asia and, on a world scale, it is rare in the tropical and subtropical belts. Within 
regions of temperate climate, MS incidence and prevalence increase with the latitude, both north 
and south of the equator (Kurtzke, 1995). MS is most common in populations of Northern 
European descent with a prevalence of approximately 100 per 100,000 (Compston 1997). The 
highest prevalence has been observed in Northeast Scotland and Orkney Island (population ca 
17,000), where a rate of over 200/100,000 has been described in the 1970s (Poskanzer et al 
1980). These figures included also clinically probable cases. The prevalence figures in Orkneys 
appear  to  be  even  higher  today  (James  Wilson,  personal  communication).  In  Kyrönmaa  in  
western Finland (population 100,000) a prevalence of 219/100,000 has been found for clinically 
definite  MS  (Tienari  et  al,  2004).  In  Mediterranean  countries  the  prevalence  rate  significantly  
decreases with the notable exception of Sardinia (Rosati et al 1987). The European north-south 
gradient is observed also in the United States where an additional east-west gradient is present, 
reflecting the possible role of Scandinavian immigration (Bulman and Ebers 1992). In Australia 
the region of high prevalence correlates with the presence of Caucasian population (Hammond et 
al 1988) even though theories explaining the geographical distribution of MS on a world scale 
by genetic clines seem unlikely (Poser 1994). In other ethnic groups MS is much rarer when 
compared to the prevalence in Caucasoids (Kurtzke 1983b). 
 
In Finland the prevalence of MS follows an uneven geographical distribution with a high-risk 
area situated in the Southern Ostrobothnia region Kyrönmaa (Figure 2) where a steady increase 
in incidence and a prevalence rate of over 200/100,000 have been reported (Sumelahti 2001; 
Tienari et al, 2004). The exceptional familial clustering of cases observed in this region 
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(Wikstöm 1975) together with specific predisposing haplotype signatures suggest the 
contribution of a genetic founder effect to the high frequency of MS (Pihlaja et al, 2003; Tienari 
et al, 2004; Kallio et al, 2009).  
 
 
 
Figure  2 – The uneven geographical distribution of MS prevalence in Finland. Vaasa region 
(depicted in black): 107/105 (CI 90-124). Seinäjoki north (depicted in white with dots): 136/105 
(CI 108-164). Seinäjoki south (depicted in with vertical lines): 219/105 (CI 190-247). Picture 
modified Tienari et al (2004). 
 
 
 
2.2 MIGRATION STUDIES 
Migration  studies  have  given  important  insight  for  the  role  of  environment  in  the  risk  of  
developing MS. The incidence of the disease in migrants seems to be intermediate between that 
of their birthplace and that of their new residence. If the migration occurs early in childhood 
(before the age 15) then the risk tends to be closer to that of the final residence (Gale 1995). In 
the UK the risk of MS in migrants from India increases in the second generation, mirroring the 
possibility of early exposure to environmental risk factors even though selection processes 
affecting the migrant population cannot be excluded (Elian 1990). 
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3. ENVIRONMENT AND MS 
 
MS is considered to be a multifactorial disease where both environment and genetics play an 
important role in its pathogenesis. Previous studies have provided good evidence that 
environmental factors play a role in the uneven geographical distribution of MS. The search for 
the environmental trigger has focused mainly on two aspects, possible infectious agents or the 
latitude-related photobiology (i.e. sunlight exposure and vitamin D deficiency) as determinants 
of the MS risk. 
 
3.1 INFECTIOUS AGENTS 
Some viruses are known to induce demyelinating disease in humans and experimental animals. 
In humans acute viral infections such as measles, chicken pox and rubella may cause post-
infectious complications like encephalomyelitis. One example is subacute sclerosing 
panencephalitis, a rare chronic, progressive encephalitis caused by a persistent infection of 
immune resistant measles virus. There are disorders such as tropical spastic paraparesis and 
Human T-cell Lymphotropic Virus (HTLV)-associated myelopathy that have an MS-like disease 
course and both are caused by the retrovirus HTLV-1. In animals Visna-Maedi virus and 
Theiler’s murine encephalomyelitis virus can mediate demyelinating diseases in sheep and mice 
respectively. Many viruses and other microbial agents have been suspected as etiological agents but 
their role in MS pathogenesis is not yet completely understood. 
 
3.1.1 VIRUSES 
In order to link the association of viral infection with the etiology and pathogenesis of MS, three 
main hypotheses have been formulated explaining the mechanism of the possible interaction.  
1. The first hypothesis postulates that molecular mimicry between viral antigen and MBP or 
other myelin antigens induces autoimmunity in genetically susceptible individuals (Fujinami and 
Oldstone 1985, Wucherpfennig et al 1995).  
2. The second hypothesis is that infection of a virus during childhood could establish a 
latent infection in the central nervous system (CNS) and reactivation of the latent virus could 
lead to the damage of the oligodendrocytes (Challoner et al 1995).  
3. The last hypothesis presupposes that viral infection may be an epiphenomenon that 
indirectly exacerbates the disease course and lesion development (Panitch 1994). 
Since 1960s a number of viral candidates has been proposed but the majority of them has failed to 
stand the test of time. The most promising etiological candidate is the Epstein-Barr virus (EBV), 
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a very common infectious agent in humans. Proposed as possible causative agent almost thirty 
years ago (Warner and Carp 1981), EBV has been strongly associated with MS since nearly all 
MS cases have been infected by the virus compared with 90% of healthy people (Ascherio and 
Munger 2007). In a prospective case-control study performed on two cohorts of US nurses, 
Ascherio and co-workers (2001) examined the association between serum anti-EBV antibody 
titers and risk of developing MS. Before disease onset, cases who subsequently developed MS 
had significantly higher anti-EBV antibody levels when compared to their matched controls. 
Furthermore, based on recent meta-analysis there is a 2.3-fold risk in developing MS if the 
subject has been infected with EBV in late childhood or adulthood (Ascherio and Munger 2007) 
and MS patients showed a significant increase in antibodies directed against EBV in the CSF 
(Bray et al 1992). Quite recently Serafini and colleagues (2007) provided the first pieces of 
evidence that a proportion of B-cells infiltrating the CNS are infected with EBV. 
 
Another interesting candidate is human herpes virus 6 (HHV-6), a neurotropic virus present in 
post-mortem MS lesions (Challoner et al 1995). Because of its ubiquitous prevalence and 
uniform early age of infection it has been impossible to compare the MS risk for infected versus 
non-infected individuals, but immunological and molecular studies have showed an increase in 
markers  of  HHV-6 infection  in  blood  cells  or  CSF of  MS cases  (Sola  et  al  1993,  Soldan  et  al  
1997). A possible gene-environmental interaction has been reported between active replication 
of HHV-6A and Major Histocompatibility Complex Trans-Activator 2A (MHC2TA) gene 
(Alvarez-Lafuente et al 2009). 
 
In late 1990s Perron and colleagues partially characterized from blood and CSF of MS patients a 
novel retrovirus, MS-associated retrovirus (MSRV), previously known as LM7 (Perron et al, 
1997). Complete MSRV sequence revealed a related new family of human endogenous 
retroviruses (HERVs), retroviral agents derived from past infections in human evolutionary 
history (Komurian-Pradel et al, 1999). The family was named HERV-W from tryptophan t-RNA 
binding site. Recently HERV-W has been shown to be expressed in the brain and activated in 
MS patients (Mameli et al 2007). However further evidence is needed to elucidate the role 
played by HHV-6 and MSRV in MS pathogenesis.  
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3.1.2 BACTERIA 
Even though common microbial infections are associated with the relapses, bacteria have been 
overlooked as etiological agents of MS. Wucherpfennig and Strominger (1995) have shown that 
both viruses and bacteria contain homologous peptide epitopes that are able to activate MBP 
primed T-lymphocytes. In the past Chlamydia pneumoniae nucleic acid has been found in the 
CSF of MS patients (Sriram et al 1998) but, after initial enthusiasm, other researchers failed to 
confirm the original results (Kaufman et al, 2002). Intriguingly non-pathogenic gut bacterial 
proteins possess the potential to act as autoimmune immunogen mimics (Westall 2006) and a 
microbial peptide, common to several bacterial classes, can induce MS-like disease in transgenic 
mice with a human leukocyte antigen (HLA) DRB1*1501 and a human T-cell receptor (TCR) 
recognizing MBP (Harkiolaki et al 2009). It is of interest that, at least in mice, the MHC alleles 
(that modulate the risk to multiple autoimmune or immune-mediated disorders) also seem to 
modulate the composition of gut bacterial flora (Toivanen et al, 2001). However, there has not 
been much research activity studying these connections. 
 
3.2 SUNLIGHT AND VITAMIN D 
There is a well-known association between MS and latitude, which intuitively correlates with 
duration and intensity of sunlight. Nearly fifty years ago Acheson and colleagues (1960) pointed 
to the role of sun exposure in MS and later vitamin D and calcium were suggested as possible 
environmental determinants of the prevalence for MS (Goldberg 1974). In a study conducted in 
the United States it has been shown that both outdoor work and residence in high sunlight area 
were protecting from the MS risk (Freedman et al 2000); a report involving 81 monozygotic 
twin pairs discordant for MS revealed that the affected twins had lower levels of sun exposure 
during childhood (Islam et al 2006). One of the first observations linking vitamin D intake to MS 
risk comes from a Norwegian study that reported lower MS prevalence in coastal villages with 
greater consumption of oily fishes, an excellent source of vitamin D (Westlund 1970).  The case-
control study of Van der Mei (2003) demonstrated low childhood sun exposure in 
Australian/Tasmanian MS patients as compared to age, sex, race and geographically matched 
controls. Multiple measures were used to estimate the magnitude of sun exposure including also 
measurement of actinic skin damage of the hands, which is an objective cumulative measure of 
sun exposure.  
 
 The beneficial role of vitamin D in MS protection has been further confirmed by longitudinal 
studies among American nurses and military personnel (Munger et al 2004, 2006). In an animal 
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model of MS, experimental autoimmune encephalomyelitis (EAE), the injection of vitamin D 
completely prevented the clinical and pathological signs of disease (Lemire et al 1991) although 
the molecular mechanisms responsible for these effects are still not clear. Recently a direct 
functional interaction between vitamin D and major histocompatibility complex (MHC) class II 
has been suggested (Ramagopalan et al 2009). Sequence analysis revealed a putative vitamin D 
regulatory element (VDRE) located in the promoter of the HLA DRB1*1501, the main 
susceptibility allele for MS. The VDRE was able to bind vitamin D and to induce increased 
expression upon stimulation with 1,25-dihydroxyvitamin D3. The authors hypothesized that a 
lack of vitamin D in utero or early in childhood could affect central deletion of autoreactive T-
cells due to less effective thymic presentation of self-antigens on HLA class II molecules. This 
finding represents thus far one the few experimental  clues for environment-gene interaction in 
determining MS risk. 
 
There is evidence for seasonal variation in the determination of MS risk. In Canadian families an 
increased MS prevalence among people born in May has been observed, whereas a reduced risk 
of developing MS is found for people born in November (Willer et al, 2005). A similar pattern 
has been observed also in Finland (Saastamoinen, manuscript in preparation). One speculative 
explanation for the seasonality would be linked with vitamin D:  the higher risk for newborns in 
May could reflect low maternal and fetal vitamin D levels during the winter (Willer et al, 2005). 
It is, however, clear that there are many other possible explanations for the observed seasonality.  
 
3.3 OTHER PROPOSED ENVIRONMENTAL RISK FACTORS 
Other environmental risk factors have been proposed for MS although the evidence is quite 
weak. The role of cigarette smoking in MS has recently gained increasing interest. Smoking has 
been associated with a faster transition from RRMS to SPMS (Hernan et al 2005), whereas 
significantly increased risk for developing MS was found in female smokers before age of 
disease onset (Hernan et al 2001). A possible rationale for smoking and MS risk might involve 
neurotoxic or immunomodulatory effects of components found in cigarettes (Smith et al 1963, 
Sopori et al 1998). Physical trauma and psychological stress have been proposed as risk factors 
of MS, but the evidence has been regarded as inconclusive. A vivid debate on this issue was 
recently witnessed on the pages of Neurology (Poser 2000; Chaudhuri et al, 2000; Lehrer 2000, 
Goodin 2000). 
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4. MS PATHOGENESIS 
 
Despite many years of intense research we still do not have a definitive model for the initiation 
and progression of MS. The extensive amount of work performed in the past has provided 
important insights about the molecular and cellular events that take place in the disease course, 
although the mechanisms underlying the pathophysiology of MS are not yet completely 
understood. 
 
In 1948 Elvin Kabat provided the first evidence for the inflammatory nature of the disease with 
the observation that MS patients have abnormally high titres of oligoclonal immunoglobulin in 
the CSF (Kabat et al 1948). Before this finding an animal model for MS, EAE, was established 
with repeated injections of rabbit brain and spinal chord extracts into primates (Rivers et al 
1933). At this time, it was not understood that these extracts elicited an autoimmune reaction 
against myelin, only in late 1940s it was discovered that EAE was an induced autoimmune 
disease (Morgan, 1947). Later, using a transgenic mouse model (with a T-cell receptor specific 
for MBP), it has been shown that peripheral activation of myelin-reactive T-cells is required in 
order to induce CNS inflammation; mice housed in a sterile environment did not develop 
demyelination (Goverman et al 1993). This finding provides a compelling link between 
environmental microbes and autoimmunity.  
 
The most established model to date for the pathogenesis of MS suggests that autoreactive T-cell 
clones specific for myelin antigen become activated in the periphery via molecular mimicry by 
viral or bacterial proteins (Figure 3). Underlying immunoregulatory defects, such as functional 
impairment of regulatory T-cells (Tregs), allow further activation of autoreactive T-cells. 
Increased  permeability  of  the  BBB leads  to  lymphoid  cell  infiltration  into  the  CNS where  the  
activated myelin-reactive T-cell clones recognize antigen presented by microglia and an 
inflammatory cascade is initiated. The disease process results in gradual loss of myelin sheath, 
although spontaneous remyelination occurs in the relapsing-remitting phase, corresponding to 
the period of the amelioration of the clinical symptoms (remitting phase) in MS patients. 
However, recurrent inflammatory attacks undermine the myelin repair system leading to reactive 
gliosis and axonal damage in the later progressive phase of the disease. 
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Figure 3. Supposed pathogenesis model for MS for type-I lesion. In Type-II lesion the effector 
cell  penetrating  BBB would  be  B-cell.  In  Type-III  lesion  the  inflammation  would  occur  at  the  
BBB or vascular wall. In Type-IV lesion the lymphocyte migration does not play such an 
important role any more, but the myelin-oligodendrocyte unit has become metabolically 
compromised. 
 
 
4.1 IMMUNOPATHOPHYSIOLOGY OF MS 
Both cell-mediated and humoral immune systems present abnormalities in MS patients, although 
it has been not trivial to distinguish between phenomena and epiphenomena. 
 
4.1.1 CELL-MEDIATED IMMUNE SYSTEM 
Autoreactive T-cells recognizing myelin epitopes are present in the peripheral blood of both MS 
patients and healthy individuals. Almost twenty years ago it was shown that among T-cells 
isolated from the blood of MS patients many clones exhibited specificity for MBP p85-99 
epitope (Ota et al 1990). More particularly, the T-cell receptor (TCR) for these clones was found 
to bind the MHC-epitope in an unconventional fashion, with the TCR making primarily contact 
with the MHC backbone rather than the antigen itself (Hahn et al 2005). Therefore autoreactive 
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T-cells would have a higher degree of functional degeneracy, as observed in the case of cross-
reactivity against other myelin epitopes with MBP-reactive T-cell clones (Ausubel et al 1996). 
This observation supports the hypothesis that molecular mimicry by viral or bacterial peptides 
could prime the myelin-reactive T-cells (Wucherpfennig et al 1995). Another challenge to the 
determination of the immunodominant epitope that initiates MS is a phenomenon known as 
“epitope spreading”. When injected with a single MBP epitope, genetically susceptible mice 
develop EAE, generating T-cells directed against the administered peptide (Lehmann et al 1992). 
During the course of the disease a T-cell population became activated also against other MBP 
epitopes and when isolated then adoptively transferred into naïve mice, these T-cells specific for 
cryptic MBP epitopes were sufficient to initiate the disease. This phenomenon seems to happen 
also in humans since most MS patients exhibit T-cell reactivity to many myelin antigens (Ota et 
al 1990). 
 
4.1.2 ROLE OF REGULATORY T-CELLS 
The presence of potentially autoreactive T-cells in the circulation of healthy individuals indicates 
that there are additional regulatory mechanisms to clonal deletion in the thymus and anergy in 
the periphery for the maintenance of immunologic self-tolerance. An important role played by 
Tregs is in preventing the development of autoimmune disorders by their inhibition of self-
antigen-reactive T-cells (Sakaguchi 2000). Often phenotypically classified as CD4+CD25high, 
human Tregs are characterized by a very heterogeneous cell population where the most specific 
marker is the nuclear transcription factor FoxP3, whose expression correlates with their 
suppressive activity (Wang et al 2007). In patients with autoimmune disorders the autoreactive 
T-cells have a lower threshold for the activation when compared to healthy controls (Reijonen et 
al 2002). In MS patients Tregs have lower levels of FoxP3 and this decrease correlated with the 
Treg loss of function (Huan et al 2005). Furthermore Astier and co-workers (2006) showed that 
CD4+CD25high Tregs isolated from MS cases are normal in frequency but poorly suppress the 
activation of autoreactive T-cells. Even though the role of functional dysfunction of Tregs in the 
pathophysiology of MS might be relevant, recently it has been shown in mice that myelin-
specific CD4+CD25high cells accumulate in the CNS but fail to control autoimmune 
inflammation (Korn et al 2007). 
 
4.1.3 HUMORAL IMMUNE SYSTEM 
Although MS has often been considered predominantly a T-cell mediated disease, the role of B-
cells in the pathogenesis has recently been reconsidered. Traditionally B-cells have been 
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implicated in MS for the production of autoantibodies against myelin and non-myelin antigens. 
These immunoglobulins can trigger the destruction of the tissue by recruiting macrophages and 
activating the complement pathway, although their relevance in MS pathogenesis has not yet 
been clarified. Among the possible pathogenic antigens, the role played by the anti-inflammatory 
heat-shock protein ??-crystallin has gained recent attention (Ousman et al 2007). In fact the 
production of antibodies directed against ??-crystallin could exacerbate the inflammation by the 
blockage of its immunosuppressive function.  
 
In other autoimmune disorders (rheumatoid arthritis, myasthenia gravis), B-cells aggregate into 
lymphoid-like structures in the target, similarly to what happens in the meninges of MS patients 
(Serafini et al 2004). Although restricted to late disease phases, the formation of ectopic 
immunological follicles in MS patients brains could provide the microenvironment for B-cells 
maturation and proliferation. Furthermore it has been demonstrated that CXCL13, a chemokine 
involved in B-cells homing to lymphoid tissues, expression was detected in the intrameningeal 
follicles and was high in the CSF of MS patients (Serafini et al 2004, Krumbholz et al 2006).  
 
4.2 ROLE OF CNS RESIDENT CELLS 
ASTROCYTES. Astrocytes have been referred to as the backbone of the CNS which provide the 
support for neuronal transmission. In addition, astrocytes foot processes are central in 
maintenance of the BBB. Moreover, they can act as non professional antigen-presenting cells 
(APC)  and  at  least  in  mouse  they  are  able  to  activate  encephalitogenic  T-cells  through  MHC  
class II (Stuve et al 2002). 
MICROGLIA. Microglia are the immune-sentinels of the CNS. They are considered resident 
macrophages of the brain and spinal chord and act as first and main form of active immune 
defence. Infiltrating macrophages and activated microglia are the key players in the initiation of 
tissue damage during the inflammatory events taking place in the CNS. In active MS plaques 
osteopontin, a protein produced by macrophages and activated microglial cells, is highly 
expressed and induces a cascade of pro-inflammatory events such as the recruitment of 
monocytes and the inhibition of T-cells apoptosis in the lesions (Chabas et al 2001, Hur et al 
2007). Microglia are important antigen presenting cells that are primed by CD4+ T lymphocytes; 
once activated they are able to secrete several molecules, such as proteases and cytokines, that 
may destroy the myelin sheath. However, the activation of microglia and macrophages with 
subsequent demyelination and tissue damage does not require the induction of the adaptive 
immune system. Various Toll-like receptors (TLRs) are expressed on both cell populations and 
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several endogenous ligands for TLRs are locally present. Injection of bacterial 
lipopolysaccharide (LPS), a ligand for TLRs and important activator of innate immunity, into the 
white matter results in demyelinating plaques (Felts et al 2005), whereas precipitated fibrin, a 
ligand for TLR4, has been found on the surface of microglial cells and macrophages in active 
MS lesions and LPS-induced inflammation (Marik et al 2007).  
 
4.3 MYELIN AND MYELINATION 
Myelin wrapped around the axons enables rapid saltatory conduction of action potentials and 
contributes to the maintenance of axonal integrity (Nave et al, 2008). In the CNS myelination is 
carried out by oligodendrocytes. In MS, demyelination is the pathological process in which 
myelin sheaths are lost as a consequence of insults targeted at oligodendrocytes. Until recently it 
was believed that the remyelination process took place only in the active lesions and was 
practically absent in chronically established plaques. The failure of myelin repair has been 
attributed to the impairment of mature oligodendrocytes generation or their inability to myelinate 
the lesions. Lately two studies have showed that in a subset of MS patients there is evidence of 
ongoing remyelination at late phases (Patrikios et al 2006, Patani et al 2007). The reason for 
such  heterogeneity  in  MS  patients  population  is  not  clear  but  it  seems  that  the  amount  of  
remyelination  correlates  positively  either  with  the  older  age  at  death  of  patients  or  longer  
duration of the disease.  
 
Another recent study has described a new molecular mechanism regulating myelination and 
remyelination in mouse (Mi et al 2007). Inhibiting the function of leucine-rich repeat and Ig-
domain-containing, Nogo receptor-interacting protein (LINGO-1) stimulates myelin formation 
and prevents progressive axonal damage in chronic EAE. This finding revealed a new pathway 
involved in the remyelination process and a potentially interesting target for human therapeutic 
applications. 
 
Finally, there has been recent interest about the possible role played by steroid hormones, 
especially sex hormones, in the remyelination process. The rational for it is that remission of MS 
symptoms is seen during pregnancy, in particular during the last trimester when estrogens and 
progesterone plasma levels are at their maximum (Confavreux et al, 1998; Houtchens 2007). 
When estriol and progesterone pellets were implanted in mice during the effector phase of 
adoptive EAE, only estriol treatment reduced the severity of EAE significantly compared with 
placebo, whereas progesterone treatment had no effect (Kim et al, 1999). However, progesterone 
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given prior to EAE induction showed a clinical benefit and produced myelinating and 
neuroprotective effects (Garay et al, 2008). Furthermore combined estradiol plus progesterone 
therapy more effectively prevented neurological deficits. 
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5. GENETICS OF MS 
 
MS is defined as complex genetic disorder where several genes are thought to play a role in the 
susceptibility to the disease. A number of loci each contribute a relatively small effect, with no 
one locus being either necessary or sufficient, and interactions with environment further increase 
complexity. Unlike Mendelian traits, where a single gene causes the disease, complex traits are 
characterized by a weaker correspondence between the presence of a predisposing genotype at a 
single genetic locus and the phenotypic outcome. This is explained by the concept of 
predisposition,  for  which  a  gene  does  not  directly  cause  the  disease  but  rather  confers  
susceptibility to it. A consequence of this phenomenon is that not all the carriers of the disease 
gene will develop the disease because of the low penetrance of the variant. Evidences for genetic 
contribution  to  MS  have  arisen  during  the  last  thirty  years  from  several  studies  such  as  racial  
differences in the recurrence risk, familial clustering of MS cases, twin and other genetic 
analyses. 
 
5.1 FAMILY AND TWIN STUDIES 
Approximately 10% of MS cases have a family history of MS, but large extended pedigrees are 
uncommon, with most of MS families having no more than two or three affected individuals 
(Willer at al 2007). Even though no clear mode of inheritance can be inferred from segregation 
analysis (Compston et al 2006), several population-based studies of familial recurrence risk have 
provided an estimate of the increased risk for MS in the relatives of patients (Sadovnick et al 
1998; Robertson et al 1996; Carton et al 1997). This familial clustering can be quantified with ?s, 
the ratio of the risk of disease in siblings of an affected individual compared with the general 
population; in the case of MS the ratio equals to approximately 15 (Sawcer 2006), a relatively 
high value when compared to more common disorders such as asthma and hypertension (for 
these conditions the sibling recurrence risk ratio is around 3 and 4, respectively). Other family-
based  analyses  such  as  adoptees  (Ebers  et  al  1995),  conjugal  pairs  (Robertson  et  al  1997)  and  
half-siblings (Ebers et al 2004) studies have highlighted the crucial role of genetic relatedness in 
the risk of developing the disease. 
 
Twin studies have been fundamental in separating genetic and environmental effects on MS 
susceptibility. A significantly higher concordance rate in monozygotic (MZ) twins as compared 
to dizygotic (DZ) twins has been replicated in several cohorts (Ebers et al 1986, Kinnunen et al 
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1987, Sadovnick et al 1993, Mumford et al 1994, Thorpe et al 1994, Willer et al 2003, Hansen et 
al 2004, Kuusisto et al, 2008) with the exception of one study (French Research Group on 
Multiple Sclerosis 1992). When previous studies are pooled together, the concordance in MZ 
twins is on average 16% while in DZ twins the value reaches 4%, suggesting evidence for 
genetic factors in MS (table 2). More particularly a MZ:DZ ratio of 4 would imply a single 
recessive gene underlying MS genetics although we know from segregational analysis this is not 
the case. Recent observations have indicated the possibility that the concordance rate for MZ 
twins might be elevated in high prevalence areas, partially explaining the lack of replication of 
the French study (Ristori et al 2006, Islam et al 2006). This implies penetrance in MZ twins 
living in Mediterranean areas is influenced by non-genetic factors, highlighting the importance 
of environmental variables at those latitudes (Ristori et al 2006). Although discordance in 
monozygotic twins is considered as proof of environmental influence, the observed differences 
in concordance between genetically identical individuals might reflect other phenomena such as 
microchimerism  (Willer  CJ  et  al  2006),  stochastic  or  epigenetic  effects  (Fraga  et  al  2005,  
Kaminsky et al 2009). 
* Only the largest study of a population was included here (to avoid overlap between studies). 
Table 2. Previously published MS twin concordance studies. 
 
REFERENCE 
 
POPULATION 
MZ 
Number of 
concordant/total 
(%) 
DZ 
Number of 
concordant/total 
(%) 
 
MZ:DZ 
RATIO 
Ebers et al., 1986 Canada 7/27 (25.9%) 1/43 (2.3%) 11.3 
Kinnunen et al., 1987 Finland 1/11 (9.1%) 0/10 (0%) n.a. 
FRGoMS, 1992 France 1/17 /(5.9%) 1/37 (2.7%) 2.2 
Sadovnick et al., 1993 Canada 8/26 (30.8%) 2/43 (4.7%) 6.7 
Mumford et al., 1994 United Kingdom 11/44 (25%) 2/61 (3%) 8.3 
Thorpe et al., 1994 United Kingdom 8/23 (34.7%) 1/41 (2.4%) 14.5 
Willer et al., 2003 Canada 37/146 (25.3%) 12/224 (5.4%) 4.7 
Hansen et al., 2004 Denmark 5/37 (13.5%) 1/171 (0.6%) 22.5 
Ristori et al., 2006 Continental Italy 4/51 (7.8%) 3/147 (2%) 3.9 
Ristori et al., 2006 Sardinia 1/8 (12.5%) 0/10 (0%) n.a. 
Islam et al., 2006 North America 56/418 (13.4%) 20/380 (5.3%) 2.5 
Kuusisto et al., 2008 Finland 3/10 (30%) 2/14 (14.3%) 2.1 
Total*  118/724 (16.3%) 41/1044 (3.9%) 4.2 
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5.2 STRATEGIES TO IDENTIFY DISEASE GENES 
In the last two decades two principal approaches have been used for localizing and subsequently 
identifying disease genes. 1. Linkage analysis in families with multiple cases. Linkage detection 
is based on co-segregation of chromosomal marker and the disease, taking advantage of the 
meiotic events in the pedigrees. 2. Assessment of allelic association, based on linkage 
disequilibrium between marker allele and disease allele, using either case-control or family-
based settings. This approach exploits the historical recombination that took place in the 
ascertained population.  
 
5.2.1 LINKAGE ANALYSIS 
Linkage analysis investigates the co-inheritance of a marker locus and a disease locus, 
identifying discrete segments of chromosomes that deviate from independent segregation and 
therefore co-segregate with the disease in extended pedigrees. Linkage studies take advantage of 
the fact that during meiosis each chromosome pairs with its partner (homologous chromosome) 
and exchange genetic material: this exchange is termed recombination and is the basis for 
detecting linkage. If two loci are in close proximity on a chromosome then the chance for 
recombination would be small. If they are far apart on the chromosome then the chance that they 
would recombine is greater. The frequency of recombination is measured in centiMorgans 
(cMs), with 1 cM equivalent to the frequency of 1% recombination. During few generations 
there is very little recombination, thus chromosomal segments of several cMs are shared 
between parents and offspring (and between siblings as well). Since linkage studies analyze the 
co-segregation of a marker locus with the disease or trait of interest, in case of linkage the 
distance between the linked markers and disease locus may be typically quite large (10-20 cMs). 
 
In standard linkage analysis the statistical significance is measured in terms of a lod score that is 
the logarithm to the base 10 of the odds for or against linkage (free recombination between 
marker and disease locus). In other words the lod score calculates the overall likelihood of the 
data by comparing the two alternative hypotheses: a lod score of 3 is considered as statistically 
significant and indicates that the observed data is 1000 times more likely if there is a disease-
linked gene in the region than if there is no disease gene in the region. This method requires the 
collection of pedigrees with more than one affected member. Traditionally, a few large pedigrees 
are considered more powerful in mapping the disease locus than several small pedigrees (Ott 
1991). 
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The linkage analysis has proven to be very successful in identifying genes responsible for 
monogenic disorders but not so effective for complex diseases with the exception of some early 
encouraging finding such as the involvement of a locus on chromosome 16 in Crohn’s disease 
susceptibility (Hugot et al, 1996; Cavanaugh et al, 2001), which led to the identification of 
NOD2-mutations (Ogura et al, 2001). 
 
In MS more than 30 datasets have been screened for linkage with different levels of resolution 
and genome coverage (Fernald et al 2005). Every study has suggested the involvement of 
different chromosomal regions with MS susceptibility but only the MHC region on chromosome 
6p21.3 has repeatedly reached and robustly exceeded the threshold for statistical significance. 
Other regions have reached the threshold for suggestive linkage (LOD between 2 and 3): 1q, 9q 
and 16p (Kenealy et al 2004), 2q27 and 5p15 (Dyment et al 2004), 5p (Dyment et al 2004, 
Kuokkanen et al 1997), 5q33 (Sawcer et al 2005), 17q22-24 (Sawcer et al 2005, Kuokkanen et al 
1997)and 19p13 after HLA-conditioned analysis (Sawcer et al 2005). The reason for such 
limited success lies probably in the design of linkage studies which are underpowered in case of 
common variants with small relative risk (i.e. relative risk <2) as susceptibility factors for 
complex disorders (Risch and Merikangas 1996). Another factor affecting the success of linkage 
is the genetic heterogeneity of the analysed disorder. Particularly locus heterogeneity, i.e. the 
involvement of different loci in the causation of a disease/phenotype, reduces the power of the 
lod score test (Morton 1955). Overall, the major utility of the linkage approach has been in 
setting an upper limit on the expected effect sizes and ruling out the presence of strong effects by 
individual loci other than the MHC region. 
 
5.2.2 ASSOCIATION STUDIES 
Compared to linkage, association studies are more powerful in detecting weak effects exerted by 
relatively common polymorphisms. Association studies determine whether specific genetic 
variants (allelic variants) predispose to disease at the population level by comparing the 
frequency of marker locus alleles in patients and matched controls. If a disorder is found to be 
associated with a particular marker allele, this may suggest a causal relationship between the 
marker allele and the disease (i.e. marker allele is the disease predisposing variant, e.g. APOE ?4 
and Alzheimer's disease, Corder 1993). More often the marker allele "marks" a neighbouring 
disease allele, a phenomenon termed linkage disequilibrium (LD). LD represents the non-
random association between alleles at two linked loci that reflects their vicinity and the 
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correspondingly low probability of recombination breaking the haplotype on which they are 
found (Bodmer, 1972). The strength of LD depends, in a given population, on several factors, 
the most important ones being the number of founding individuals (number of founding 
haplotypes) and the time since founding (Shifman et al, 2001). With each generation 
recombination tends to reduce LD, erasing the association between alleles except for markers 
located in the close proximity of the susceptibility locus. Just as linkage exploits recombination 
within current families, linkage disequilibrium (i.e. association) studies take advantage of the 
many recombination events that occurred historically in a population. As a result, association 
due to linkage disequilibrium occurs over short distances, typically much less than 1 Mb, and 
therefore association studies are often used to fine-map the disease locus identified from a 
previous linkage peak. 
 
The major paradigm for case-control association studies in the last years has been the common-
disease common-variant (CDCV) hypothesis which assumes that much of the genetic variation 
of complex common disorder is due to relatively few common variants. The proposed rationale 
for genotyping common polymorphisms (i.e. variants with a population allele frequency ? 5%) 
is  that  common SNPs can  significantly  contribute  to  disease  prevalence  even  if  their  effect  on  
disease risk is  modest (Reich et  al,  2001).  At the same time an alternative view on the genetic 
architecture of complex disorders, the rare variant hypothesis, has been proposed. The rare 
variant hypothesis assumes that susceptibility to common disorders is due to numerous low 
frequency polymorphisms, each conferring a moderate but detectable increase in relative risk 
(Bodmer et al, 2008). A comparison of both hypotheses is given in table 3 with emphasis on the 
main differences between them. Probably both models are correct and not necessarily mutually 
exclusive as there is evidence for both. It is worth noting that if the rare variant hypothesis is 
true, association studies have inadequate power to detect causative variants since the multitude 
of rare alleles (whose overall frequency would be high enough to be responsible for the 
susceptibility of a common disease) would not be tagged by any marker or haplotype. 
 
Following the recent progress in laboratory techniques, association studies covering the whole 
genome (genome-wide association studies, GWASs) have become readily available for testing 
common variation without any assumption about the nature of the genes that influence the 
disease. In the last two years GWASs have been successful in identifying loci responsible for the 
susceptibility to complex disorders (Rioux et al 2007, Saxena et al 2007). To date, four GWASs 
have been performed in MS, (IMSGC 2007, WTCCC 2007, Baranzini et al 2009, ANZgene, 
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2009) yielding interesting findings. The IMSGC study published a family-based approach using 
500,000 SNPs genotype on Affymetrix/Illumina arrays in 931 trios. The most significantly 
associated SNPs were analyzed in a second dataset of 2931 cases and 4205 controls as well as in 
pooled material (using a total of 12360 individuals). 
 
The WTCCC used a case-control approach scanning for 14,500 non-synonymous SNPs in 975 
MS patients. Although lacking replication this study has partially confirmed some leads from the 
IMSGC and proposed new susceptibility loci whose role has to be confirmed in other studies. A 
study from Baranzini et al (2009) has reported the results from a GWAS performed in 1000 
well-characterized  MS  and  an  equal  amount  of  matched  controls.  They  have  compared  allele  
frequencies of over 500000 SNPs in the two cohorts and their influences on several disease-
related variables. Recently a GWAS from the Australia and New Zealand MS Genetic 
Consortium (ANZgene, 2009) has been published. Two independent datasets for a total of 3874 
cases and 5723 controls were analysed and several known MS associations were replicated. The 
results from these studies and their relevance in MS predisposition are discussed in more details 
in the section 5.4. 
 
                             CDCV                       RARE VARIANTS 
Usually detectable with population-based case-
control association studies (genome-wide 
association studies, candidate gene studies) 
Usually detectable with DNA sequencing of 
candidate genes in selected patients 
Usually risk allele frequency > 10%* Risk allele frequency < 5%* 
Variants are shared by most human populations Population-specific variants 
OR < 2* OR ? 2* 
The impact of the variant on the function is not 
often obvious 
 
 
Examples: 
APOE ?4 in Atherosclerosis1 and Alzheimer’s 
disease2 
PPARG in type-2 diabetes mellitus3 
 
Variants more often have structural effect on 
protein function, help in understanding disease 
etiology 
 
Examples: 
NOD2 in Crohn’s disease4 
ABCA1 in atherosclerosis5 
* These are estimates, the exact values cannot be defined. 
1 van Bockxmeer and Mamotte 1992. 2 Corder et al 1993. 3 Altshuler et al 2000. 4 Lesage et al 2002. 5 Cohen et al 
2004. 
 
Table 3. Comparison of the two main hypotheses regarding the genetic architecture of common 
disorders. 
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5.2.3 ROLE OF GENETIC ISOLATES 
Genetic isolates have significantly contributed in the identification of genes for rare Mendelian 
disorders. The peculiarities of such populations have appealed to geneticists over time and in 
recent years there has been some discussion about their role in mapping complex diseases 
(Peltonen et al, 2000). Population isolates, like the Finns, exhibit significantly less genetic 
diversity at chromosomal and mitochondrial DNA level (Sajantila et al,1996; Kittles et al, 1998). 
A consequence of that is the increased signal-to-noise ratio: etiologic homogeneity of common 
diseases (i.e. allelic and locus heterogeneity) increases the chances of detecting a significant 
signal. In genetic isolates the genetically homogenous population allows the detection of novel 
associations with a relatively small amount of patients. Furthermore cultural and environmental 
homogeneity in such genetically homogenous populations decreases the effect of penetrance and 
phenocopies in the manifestation of complex diseases. 
 
One example has been the discovery of the role of MBP in MS susceptibility in the Southern 
Ostrobothnian isolate (Pihlaja et al, 2003). Furthermore LD of markers with rare disease alleles 
extends over greater distances in young population isolates and enables one to use fewer markers 
in an association study. Recently Sabatti and colleagues have identified a rare variant (minor 
allele frequency = 0.017) of the gene on chromosome X in part responsible for sex-specific 
dyslipidaemias. The study was carried out in a selected sample material (Northern Finnish Birth 
Cohort 1966), pointing out the possible importance of GWAS in the discovery of infrequent 
variants when carried out in individuals sharing distant ancestors.  
 
5.3 ROLE OF HLA GENES 
Several linkage and association studies have pinpointed the role of chromosomal region 6p21.3 
as  the  major  player  in  MS  susceptibility.  More  particularly  the  genetic  signal  maps  to  a  wide  
area spanning the HLA gene complex which includes many proteins associated with immune 
functions (Figure 4). There are two major classes of HLA genes encoding for highly 
polymorphic heterodimeric glycoproteins involved in the immune recognition of self from non-
self. The telomeric distal region contains class I genes (HLA-A,-B,-C) whereas in the proximal 
centromeric segments are present the class II genes (HLA-DR,-DQ,-DP). While both ? and ? 
chains of the class II proteins are encoded by the MHC region, only the ? chain of the class I is 
encoded by HLA, with the non-polymorphic ?2-microglobulin (the ? chain of the class I protein) 
being encoded on chromosome 15. A third group of genes, generally known as class III and 
positioned  between  the  class  I  and  II  region,  encodes  for  e.g.  complement  proteins,  tumor  
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necrosis factor and heat shock proteins. The HLA complex is characterized for its high levels of 
polymorphic variation and the extent of non-random association between alleles in the region 
(Horton et al 2004). 
 
Initially the association between HLA and MS was reported with the class I region (Naito et al 
1972, Jersild et al 1972) and subsequently also with class II (Jersild et al 1973); rather quickly it 
was established that these observations were not independent associations but the result of the 
strength  of  the  LD  present  among  alleles  of  different  loci  on  the  same  haplotype,  with  the  
association primarily deriving from the class II region (Compston et al 1976, Terasaki et al 
1976). 
 
Using the modern nomenclature, it was clear that the association signal was segregating with the 
extended haplotype HLA-DQB1*0602, HLA-DQA1*0102, HLA-DRB1*1501 but the fine-
mapping of the susceptibility locus has been complicated by the extensive LD between DRB1 
and DQB1. Using a MS cohort of African-American ancestry where the LD pattern is less 
intense, a selective association with HLA-DRB1 independent of DQB1 was reported (Oksenberg 
et al 2004), providing evidence for a primary role of this locus in MS predisposition. 
Subsequently, Yeo et al (2007) have replicated this finding in a large dataset of European 
patients but the functional role of HLA-DRB1 gene regarding MS susceptibility still remains 
elusive. Structural studies have indicated that HLA-DRB1*1501 can bind with high-affinity a 
peptide deriving from MBP, one of the most studied putative autoantigens (Smith et al 1998). 
 
In the study of Oksenberg and colleagues (2004) HLA-DRB1*1501 was not the only allele that 
associated with the disease. Since this variant has low frequency in Africa the analysis provided 
also a role for HLA-DRB1*1503 and HLA-DRB1*0301 alleles. It is now clear that the risk 
carried by HLA-DRB1*1501 allele may be modified depending on which MHC haplotype is 
present in the heterozygous state (Dyment et al 2005, Barcellos et al 2006, Ramagopalan et al 
2007). Also a role for the existence of an independent signal from class I region has been 
proposed in several studies but the extent of LD in the region has complicated its dissection 
(Marrosu et al 2001, Rubio et al 2002, Yeo et al 2007). A modifier gene has been suggested to 
be  located  in  the  class  I  region  (Friese  et  al  2008)  and  in  the  HLA-DRB5 (Etzensperger  et  al  
2008). 
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Figure 4. Genomic organization of the HLA complex. The arrow indicates the primary role 
played by HLA-DRB1 gene in MS susceptibility. 
 
 
 
5.4 ROLE OF NON-HLA GENES 
The MHC region alone explains only a portion, approximately less than half, of the heritability 
of MS. In the last few years the GWAS and other studies have shed some light into the genetic 
architecture that lies behind the susceptibility to MS, producing of list of genes whose 
association with the disease has been replicated in more than one dataset (Table 4). Below I 
discuss in more detail the most significant loci associated with MS and their possible 
involvement in the disease pathogenesis.   
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LOCUS 
 
CHROMOSOME ASSOCIATED 
COHORTS 
FUNCTION 
IL-7R 5p13 UK, US, multiple  Immunological 
IL-2RA 10p15-14 UK, US, Canadian, multiple Immunological 
PRKCA 17q22-24 UK, Finnish, Canadian Immunological 
TYK2 19p13 meta-analysis Immunological 
CD58 1p13 meta-analysis Immunological 
EVI5/RPL5 1p22 Dutch inbred, Canadian Immunological? 
KIF1B 1p36 Dutch inbred and outbred, 
Canadian 
Neurological (axonal 
transport) 
CLEC16A 16p13 IMSGC, Sardinia Immunological 
IRF5 7q32 Spanish, Swedish, Finnish Immunological 
CD226 18q22 UK, US, IMSGC Immunological 
MBP 18q23 Finnish, Russian, Italian, 
multiple 
Myelination 
IRF8 16q24 meta-analysis Immunological 
CD6 11q13 meta-analysis Immunological 
C7-FLJ40243 5p13 Finnish isolate, Finnish, 
Sweden and others 
Immunological 
TNFRSR1A 12p13 meta-analysis Immunological 
Table 4. Non-HLA genes implicated in MS susceptibility on the basis of genetic analysis in 
more than one population. Multiple = the locus has been associated with MS in three or more 
populations. Meta-analysis = genome-wide significant evidence of association in a meta-analysis 
of several populations. 
 
 
5.4.1 IL-7R 
Already studied as a candidate gene (Teutsch et al 2003, Zhang et al 2005), the role of the 
interleukin-7 receptor (IL-7R) in MS susceptibility has been unequivocally confirmed by two 
simultaneous independent analyses (Gregory at al 2007, Lundmark et al 2007) which have 
shown an association with the SNP rs6897932. The associated polymorphism (a non-
synonymous variation, T244I) is situated in the alternatively spliced exon 6 of the gene that 
encodes for the transmembrane domain. If exon 6 is included then the transcript encodes for a 
membrane receptor whereas if it is skipped then the mature protein will be a soluble receptor 
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(Gregory et al 2007). The associated variant increases the proportion of soluble receptor in the 
bloodstream and therefore is predicted to affect the IL-7R signalling. It is worth noticing that the 
risk allele is very common, found in 76 % of patients and 72% of controls (IMSGC 2008): 
carriers of the associated variant have only a 20% increased risk of developing MS (OR = 1.2).  
 
5.4.2 IL-2RA 
The IMSGC study has indicated a role for the interleukin-2 receptor alpha subunit (IL-2RA) 
with two SNPs in moderate LD with each other associating with MS. This finding has been 
replicated in an independent Canadian cohort (Ramagopalan et al 2007) and it strongly points 
toward the importance of the IL-2 pathway in MS susceptibility. It is important to notice that 
these findings are in line with earlier results obtained in type-1 diabetes, rheumatoid arthritis and 
Graves disease, suggesting a possible common pathogenetic mechanism underlying 
autoimmunity. Furthermore the relative risk attributable to variation in both IL7R and IL-2RA 
(OR = 1.2; IMSGC 2008) is very low and explains only a little part of the variance in the risk of 
MS.  
 
5.4.3 OTHER GENES 
Protein kinase C alpha (PRKCA) gene is located on chromosome 17q22-24, a region that has 
revealed indicative linkage in Finnish MS pedigrees (Kuokkanen et al 1997). A role for PRKCA 
in MS susceptibility has been further suggested by association study in a UK patient population 
(Barton et al 2004). Subsequently a LD-mapping study in both Finnish and Canadian MS 
families confirmed the presence of multiple signals within the PRKCA locus (Saarela et al 
2006).  Although  the  SNPs  associated  with  MS  were  different  in  the  two  populations,  the  risk  
haplotypes covered the same genomic region, stretching from intron 3 to intron 8. Expression 
analysis revealed a weak genotype-phenotype correlation in CD4- cells,  with  lower  levels  of  
PRKCA in individual possessing two copies of the risk haplotype. PRKCA has been implicated 
in T-cell activation for its involvement in the regulation of the IL-2 pathway, suggesting a 
possible disregulation of the signal transduction in MS. 
 
Hoppenbrouwers and colleagues (2008) have verified the risk contribution of the best associated 
SNPs  from  the  IMSGC  study  (2007)  in  MS  patients  from  a  Dutch  genetically  isolated  
population. Apart from a HLA-DRB1 SNP, two polymorphisms in the EVI5 (ecotropic viral 
integration site 5) gene were confirmed as risk variants and were also replicated in an 
independent Canadian cohort of MS patients. EVI5 is a common site for retroviral integration 
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and it could possibly link the involvement of retroviral elements to MS pathogenesis; it is not 
clear though if the causative variant lies within EVI5 or its neighbouring genes, such as RPL5 
(ribosomal protein L5). 
 
Kinesin family member 1B (KIF1B) has been initially associated in a GWAS performed on the 
same genetically isolated Dutch population and subsequently replicated in an outbred Dutch and 
Canadian trio families (Aulchenko et al 2008). The locus encodes for a member of the kinesin 
superfamily and is believed to be involved in the axonal transport of mitochondria and synaptic 
vescicle (Nangaku et al 1994, Boldogh et al 2007). The most strongly associated SNP (p-
values<2.5*10-10) with MS is located in intron 5, although the causative variant is not known. 
Nevertheless this finding represents a non-immunologically related gene in MS predisposition. 
Its possible association with MS has not yet been reported in other populations than Dutch and 
Canadian materials. 
 
The WTCCC study uncovered the possible involvement of tyrosine kinase 2 (TYK2) gene in MS 
pathogenesis.  In  a  replication  study,  Ban  et  al  (2009)  found  an  association  signal  of  the  same  
marker located in the exon 21 of the gene. The associated SNP encodes for an amino acid 
change (proline to alanine) in the kinase domain which is predicted to affect the phosphoryation 
and hence the activity of the protein. 
 
A GWAS suggested a role for CD58 in MS predisposition (IMSGC, 2007). Following this 
finding De Jager and co-workers (2009) re-sequenced and fine-mapped the CD58 locus in case-
control approach. The results revealed a SNP significantly associated with protection from MS. 
 
Already associated with type I diabetes, the polymorphism Gly307Ser CD226 has been found to 
be associated also with MS (Hafler et al, 2009). The functional impact of the variant on the 
protein is not clear yet. 
 
A variant located in CLEC16A (c-type lectin domain family 16, member A) locus showed 
suggestive evidence of association with MS in a GWAS (IMSGC 2007). Zoledziewska and 
colleagues (2009) genotyped another SNP (rs725613) in the same gene but not in LD with the 
variant  in  a  case-control  cohort  of  MS and  type  1  diabetes  (T1D)  patients.  The  polymorphism 
associated at a significant level with both MS and T1D, bringing the evidence for a possibly 
shared disease pathway. 
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In a meta-analysis of GWASs for MS three new susceptibility loci were identified with genome-
wide significance, p < 5 x 10-8 (De Jager et al, 2009). Two polymorphisms within the tumor 
necrosis factor receptor superfamily, member 1A (TNFRSF1A) genomic region  associated with 
the disease. One of them (rs1800693) is located in the fourth intron and it is relatively common 
(allele frequency of 57%) whereas the other polymorphism encodes for an amino acid change, 
R92Q, and it is found in only 2% of the population. These results link both a common 
polymorphism of modest effect and a rare variant of stronger effect to MS susceptibility. 
 
Interferon responsive factor 8 (IRF8)  locus  was  also  associated  with  MS  although  the  
significantly associated variant lies 60 kb from the gene (De Jager et al, 2009). An expression 
analysis showed no correlation between the SNP and IRF8 transcript levels and therefore the 
role of the variant remains unknown. 
 
The other genomic region associated with MS was the CD6 locus which encodes for a molecule 
involved  in  T-cell  differentiation  and  in  the  regulation  of  tumor  necrosis  alpha  (TNF?)  serum  
levels (De Jager et al, 2009). The SNPs showing evidence for association with MS locates in the 
first intron of the gene and might have functional effects together with the variants present in 
TNFRSF1A locus. 
 
Using the genetic isolate of Southern Ostrobothnia Kallio et al (2009) have analysed the 
previously associated chromosomal region 5p. The haplotype analysis excluded a major role for 
IL7R in MS susceptibility in the sample material, with most of the association signal covering 
the C7 locus  (complement  component  7).  The  result  was  replicated  in  another  independent  
dataset from the isolate and a suggestive association was seen also in other more heterogeneous 
populations. Furthermore the complement activity significantly correlated with the identified 
risk haplotype. 
 
MBP is an obvious candidate gene for its potential role as target for immune-mediated 
mechanisms involved in MS pathogenesis. Evidence for association between the disorder and a 
short tandem repeat located in the promoter of the gene has been found in linkage and 
association studies (Tienari et al 1992; Tienari et al 1998). Further association has been reported 
in Italian, Danish and Italian-Russian studies although the analyses were performed with 
different markers (Ibsen and Clausen 1996, Guerini et al 2000, Guerini et al 2003). The reason in 
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the lack of replication among different populations might be due to the geographical restriction 
of the association between MS and the microsatellite marker utilized in the Finnish study. 
Pihlaja and colleagues (2003) indeed confirmed the previously reported association only in the 
high incidence region of Southern Ostrobothnia.   
 
However  it  is  important  to  stress  that  case-control  studies  are  prone  to  false  results  as  a  
consequence of population stratification. Although different algorithms have been developed to 
assess the presence of genetic subgroups in mixed populations, the combination of case-control 
and family-based analyses is the best option to avoid spurious associations. It is also worth 
noting that several GWAS hits mentioned above (De Jager et al 2008, Hafler 2009, 
Zoledziewska 2009) have been found only in case-control datasets and hence these findings need 
further replication also in family-based material. 
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AIMS OF THE PRESENT STUDY 
 
 
MS is a complex disorder where both genetic and environmental factors have been implicated 
but its etiology and pathogenesis still remain poorly understood. The purpose of this study was 
to investigate the role of chromosomes 2q33, 19q13 and IRF5 in MS. 
 
Three chromosomal regions previously associated with other autoimmune disorders have been 
analyzed in MS datasets to evaluate their role in the susceptibility to the disease.  
(i) The 2q33 region has been extensively studied in respect with its possible role in other 
autoimmune diseases. In MS the results have been conflicting and primarily focusing on the 
costimulatory immune regulator CTLA-4. The goal was to perform a two-stage association 
analysis to investigate the role of this chromosomal region in the pathogenesis of MS. 
(ii) The 7q32 region and more particularly the IRF5 gene have been already associated with 
systemic lupus erythematosus, rheumatoid arthritis and inflammatory bowel disorder. The goal 
was to investigate whether variation in the IRF5 locus would be associated with another putative 
autoimmune disorder such as MS.  
(iii) The 19q13 region has exhibited clustering of putative predisposing loci in several 
autoimmune disorders. In MS the situation is presently ambiguous with several reports providing 
weak evidence for a susceptibility gene. The goal here was to perform an allelic association 
study in order to obtain evidence of an MS susceptibility locus. 
(iv) As a follow-up of (i) we focused on the expression of the inducible T-cell co-stimulator 
(ICOS)  gene.  The  goal  was  to  characterize  the  transcriptional  regulation  of  the  locus  with  
attention to alternatively spliced isoforms. 
 
Since MS is a genetically heterogeneous disease, this study takes advantage of the relative 
genetic homogeneity of the Finnish population to find some of the MS predisposing genes. The 
objective of this approach will shed a new light into the pathogenesis of the disease and provide 
new tools to identify individuals at higher risk for possible preventive strategies. 
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MATERIALS AND METHODS 
 
1. SUBJECTS AND FAMILIES (I-IV) 
All patients had clinically definite or laboratory-supported definite MS according to the Poser 
criteria. No selection was made as to the disease course, hence there were patients with 
relapsing-remitting, primarily progressive and secondary progressive course. All samples were 
taken with oral or written informed consent. The studies were approved by ethical committees of 
Helsinki University Central Hospital (Decision 46/2002, Dnro 192/E9/02) and collaboratory 
institutes.  The study material included: 
Study I: 134 and 186 Finnish MS trio families in stage-1 and stage-2 respectively. Linkage 
analysis was performed in 27 multiplex families MS families. Samples were collected from the 
University  Central  Hospitals  in  Helsinki,  Tampere,  Kuopio,  Oulu  and  the  Central  Hospital  of  
Seinäjoki. 
Study II: 660 Spanish MS cases and 833 controls (samples were collected from hospitals 
located in Granada, Malaga and Sevilla), 1166 Swedish MS cases and 1235 controls (samples 
were collected from Danderyd’s Hospital or Karolinska University Hospital in Huddinge or in 
Solna, all located in the Stockholm County of Sweden), 511 Finnish MS trio families (samples 
were collected from the University Central Hospitals in Helsinki, Tampere, Kuopio, Oulu and 
the Central Hospital of Seinäjoki). 
Study III: 459 and 323 Finnish MS trio families in dataset-1 and dataset-2 respectively. 
Samples were collected from the University Central Hospitals in Helsinki, Turku, Tampere, 
Kuopio, Oulu and the Central Hospital of Seinäjoki. 
Study IV: 505  Finnish  MS  trio  families.  Samples  were  collected  from  the  University  Central  
Hospitals in Helsinki, Tampere, Kuopio, Oulu and the Central Hospital of Seinäjoki. 
The overlaps between different Finnish study materials in this thesis study are shown in table 5. 
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Study Dataset Cohort-1 
(N=136) 
Cohort-2 
(N=124) 
Cohort-3 
(N=201) 
Cohort-4 
(N=323) 
I 1 134/1361    
I 2   186/2011  
II    201/201 310/3231 
III 1 134/1361 124/124 201/201  
III 2    323/323 
IV    188/2011 317/3231 
Table 5. Overlap between different study populations in the Finnish datasets. 1 The analysis was 
performed on samples with enough material left. There was no bias in sample selection. 
 
 
2. DNA ANALYSIS (I-IV) 
DNA was extracted from blood peripheral leukocytes using standard procedures. The 
genotyping of the samples was performed as illustrated below. 
Study I: Two methods were employed in microsatellite genotyping in the association analysis: 
ABI Prism system with fluorescently labeled primers or autoradiography of the polyacrylamide 
gels using 33P-?-dATP in the PCR mixtures. The SNPs were amplified by PCR and genotyped 
by restriction enzyme digestion followed by agarose gel electrophoresis. 
Study II: The SNPs were genotyped using multiplex fluorescent minisequencing (single-base 
extension) with the SNPstream system (Beckman Coulter). The CGGGG indel was amplified by 
PCR using fluorescent primers with subsequent fragment analysis on an ABI PRISM® 3730 
DNA Analyzer. 
Study III: Microsatellites were genotyped by autoradiography of the polyacrylamide gels using 
33P-?-dATP in the PCR mixtures. The SNPs were amplified by PCR and genotyped by restriction 
enzyme digestion followed by agarose gel electrophoresis or by solid-phase minisequencing. 
Study IV: Genotyping for 17 SNPs was performed using  Sequenom MALDI-TOF mass 
spectrometry (MassArray Compact Analyzer; Sequenom Inc, San Diego, CA, USA) based on 
matrix-assisted laser desorption/ionization–time of flight technology and primer extension 
chemistry. The remaining SNPs were amplified by PCR and genotyped by restriction enzyme 
digestion followed by agarose gel electrophoresis or by solid-phase minisequencing. 
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3. STATISTICAL ANALYSES (I-IV) 
The statistical analyses were performed as follows: 
Study I: Transmission disequilibrium test (TDT) was used to perform allelic association 
analysis. The genotype data was tested using the TRANSMIT 2.5.2 computer program package. 
Two-point linkage analysis was performed with the MLINK program of the LINKAGE package. 
Study II: The PLINK software was used to compare the allele counts in cases and controls by 
Fisher’s exact test, to calculate odds ratios and also to perform the sliding window haplotype 
association analysis. The Haploview v.3.3. software was used to determine linkage 
disequilibrium (LD) between the polymorphisms. In the family cohort, the genotype data was 
analyzed using the TRANSMIT 2.5.2. computer program package. 
Study III: TDT was performed on family material as illustrated in study I. In case-control 
association analysis the haplotype frequency estimation was performed using the expectation-
maximisation algorithm as implemented in the HAPLO program. 
Study IV: TDT was performed as illustrated in study I. 
 
4. ELECTROPHORETIC MOBILITY SHIFT ASSAY (II) 
Biotinylated and unlabelled double stranded DNA probes were generated for each allele of the 
polymorphism. The labelled probe was incubated for 20 minutes with a nuclear extract prepared 
from blood cells. Competition assays were performed with a 100-fold molar excess of unlabelled 
probe. The binding reactions were run on 6% polyacrylamide gel electrophoresis and transferred 
to nylon membranes. The biotinylated bands were detected using a chemiluminescent procedure.  
 
5. PROXIMITY LIGATION ASSAY (II) 
Polyclonal antibody against SP1 was biotinilated, diluted in a saline buffer and then combined 
with a streptavidin-oligonucleotide conjugate. Partially double stranded DNA probes were 
incubated with Jurkat nuclear extract for 30 minutes at room temperature. Anti-SP1-DNA 
conjugate was added to the mixture and incubated for 2 hours at 20ºC. After the incubations 
ligation and PCR detection were performed. 
 
6. CELL CULTURE AND T-CELL ACTIVATION (IV) 
African green monkey kidney Cos-7 cells were grown in Dulbecco's modified Eagle's medium 
(DMEM; BioWhittaker) supplemented with 10% FCS. Human primary lymphocytes and Jurkat 
E6-1 were cultured in RPMI 1640 with 2mM glutamine supplemented with 10% FCS. 
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In order to purify CD4+ T-cells, blood samples (40 ml) were obtained from healthy donors and 
placed into BD Vacutainer CPT tubes (Becton Dickinson, Franklin Lakes, NJ, USA). Peripheral 
blood cells were pelleted at 1800 xg for 30 minutes. The supernatant representing the 
mononuclear fraction was washed twice in phosphate-buffered saline solution (PBS) 
subsequently used for lymphocytes isolation. 
CD4+ T-cell purification was performed utilizing a magnetic cell separation strategy. Untouched 
T-cells were isolated from peripheral leukocytes fraction with Pan T-cell Isolation Kit II 
(Miltenyi Biotech) according to manufacturer’s instructions. CD4+ T-cell were then further 
purified by depleting the CD8+ fraction with CD8 MicroBeads (Miltenyi Biotech). 
For the activation of lymphocytes, 106 cells were incubated for 6 h with phorbol myristyl acetate 
(PMA) 30ng/ml and ionomycin 300ng/ml and subsequently harvested for the suitable assay. 
 
 
7. RNA EXTRACTION AND REVERSE TRANSCRIPTASE POLYMERASE CHAIN 
REACTION (RT PCR) (IV) 
Total RNA was purified from peripheral leukocytes with the Rneasy Mini Kit (Qiagen) 
according to the manufacturer’s instructions. cDNA was synthesized from total RNA using M-
MLV polymerase according to the manufacturer’s instructions, with random RNA hexamer 
primers  (Promega).  Subsequently  cDNA  was  used  as  template  for  PCR  reaction  and  PCR  
products were resolved with 2% agarose gel. 
 
8. EXPRESSION VECTORS (IV) 
The ?ex2-ICOS and the ICOS expression vectors were obtained by respectively amplifying  
?ex2-ICOS and ICOS coding regions from mRNA of healthy donors’ peripheral leukocytes. 
PCR products were gel-purified and subcloned into pCMV plasmid. The green fluorescent 
protein (GFP)-?ex2-ICOS and GFP-ICOS expression vectors were obtained by subcloning 
respectively ?ex2-ICOS and ICOS coding regions into pEGFP-N1 (Clontech). All clones were 
verified by sequence analysis. 
 
9. TRANSFECTION AND CELL LOCALIZATION (IV) 
A round glass coverslip was placed in each well of a 6-well plate. COS-7 cells were then seeded 
at 45% cell confluency on the coveslips in 1 ml of culture medium. After 24 h 4 µg of green 
fluorescent protein (GFP)-expressing vectors were mixed with Lipofectamine 2000 (Invitrogen, 
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Carlsbad, CA, USA) according to the manufacturer’s instructions. After 24 h the cells were 
stained with ER-tracker Red (Molecular Probes), Hoechst (Molecular Probes) and subsequently 
fixed for 10 minutes with 4% paraformaldehyde.  
 
10. GEL ELECTROPHORESIS AND WESTERN BLOTTING (IV) 
In order to obtain whole cell extracts, human primary lymphocytes and Jurkat E6-1 were 
pelleted at 800 xg for 5minutes. The cell pellets were suspended and washed once in PBS. The 
cell pellet was subsequently resuspended in CHAPS 1% in PBS, supplemented with protease 
inhibitors (Complete Protease inhibitor, Roche, Basel, Switzerland), incubated at 4 ºC for 30 
minutes and centrifuges at 16,600 xg for 20 minutes at 4 ºC. The supernatant (“whole cell 
extracts”) was used immediately for protein quantification and protein detection or stored at –80 
ºC. 
Whole  cell  extracts  were  resolved  by  SDS-PAGE  on  12%  Tris-glycine  gels.  Proteins  were  
blotted to nitrocellulose with a semi-dry transfer apparatus with 25mM Tris, 190mM glycine and 
20% methanol. Membranes were blocked for 1 h at room temperature in 5% milk in TBST 
(20mM Tris, 140mM NaCl, 0,1% Tween) and incubated with primary antibody (sc-25585, Santa 
Cruz Biotechnology, Santa Cruz, CA; 1:200 dilution) overnight at 4?C. After washing in TBST, 
membranes were incubated with horseradish-peroxidase-conjugated secondary antibodies 
(1:10,000 dilution) for 1h at room temperature. Chemiluminescent detection was performed 
using ECL Plus on X-Omat AR films. 
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RESULTS AND DISCUSSION 
1. CHROMOSOME 2q33 AND MS
Chromosome 2q33 has been implicated in the predisposition of several immune-mediated 
disorders. Most studies have focused on the role of Cytotoxic T Lymphocyte Associated 4 
(CTLA4) gene, which encodes for a protein involved in co-stimulatory down-regulation of 
immune responses. 
A two-stage study was performed to analyse the association of polymorphisms of chromosome 
2q33 with MS. Stage-1 served for setting the hypothesis to be tested in stage-2. In all 17 
markers, both SNPs and microsatellites, were genotyped (figure 5). Two independent association 
signals were detected, one with the SNP marker rs3977 and the other with the microsatellite 
d2s1271. Both signals were obtained outside of the CTLA-4 locus and therefore we could not 
find any support for its candidacy in MS susceptibility.  
Figure 5. Genomic organization of the markers used in stage-1. 
We  went  on  to  fin e-map  the  obtained  association  signals.  The  association  with  rs3 9 7 7 was  
origin ally  found  in  a  two  ind epend ent  d atasets  (consisting  of  1 3 4 and  1 8 6 trio  families)  after  
HLA-DR15 stratification in the non-DR15 stratum (p=0.02 in both datasets). In order to further 
verify the above association signal, we analysed four additional markers flanking rs3977 (two 
microsatellites and two SNPs) and rs3977 as well within a 250 kb region in a new set of 309 
Finnish MS trio families. No association with MS was found and we concluded that the initial 
finding with rs3977 was a false positive obtained by chance. 
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Initially we found an association  with a 186bp allele of marker D2S1271 in two independent 
Southern Ostrobothnian set of families (stage-1 p=0.01 and stage-2 p=0.008). The candidate 
region defined by the marker D2S1271 is relatively large (approximately 300kb) based on 
linkage disequilibrium analyses, including two putative genes and two previously known genes 
(figure 6). 
 
 
 
 
 
 
 
Figure 6. Genomic organization of the LD block centered around d2s1271. The vertical arrows 
indicate the genotyped markers. 
 
 
In this genomic context the inducible T-cell co-stimulator (ICOS) gene is an obvious candidate 
for a role played in MS pathogenesis. It encodes a protein belonging to the family of Ig-like 
costimulatory receptors on the surface of T-cells. It delivers positive signals upon binding to its 
ligand, ICOS-L, and it is sequentially induced following T-cell activation. Previous studies have 
uncovered a heterogeneous role of ICOS in autoimmune disorders. ICOS-deficient mice are 
more vulnerable to EAE but are relatively resistant to experimental autoimmune myasthenia 
gravis and collagen-induced arthritis (Rottman et al, 2001; Scott et al, 2004; Nurieva, 2005). 
Furthermore in wild type mice, neutralizing antibodies against ICOS exacerbate EAE in the 
priming phase but inhibits it in the efferent phase (Rottman et al, 2001).  
 
Sanroque mice carry a homozygous mutation in ROQ domain of Roquin, a ubiquitin ligase 
family member, that acts as a repressor of ICOS (Vinuesa et al, 2005). Such mutation disrupts 
the function of the protein, causing increased ICOS expression on T-cells and a systemic lupus 
erythematosus (SLE)-like syndrome. More recently Yu and colleagues (2007) have uncovered 
the underlying molecular pathway. ICOS expression is normally tightly regulated post-
transcriptionally by a mechanism that involves a complementary conserved microRNA 
(miRNA) binding site for miR-101 located to the 3’ untraslated region (UTR) of ICOS. Roquin 
usually inhibits ICOS expression by promoting the degradation of ICOS mRNA into the stress 
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granules, specialized cell structures involved in mRNA degradation (Newbury et al, 2007). It is 
not clear though whether Roquin mediates ICOS degradation by binding directly to its target 
mRNA or to the complementary miRNA.  
 
Moreover  the  ICOS  locus  forms  a  gene  complex  with  HERV-H,  a  member  of  the  human  
endogenous retroviruses. HERV-H is located distally and in antisense orientation compared to 
ICOS (Figure 7).  
 
 
 
 
 
 
 
 
 
Figure 7. Schematic representation of the ICOS/HERV-H gene complex and its distance from 
the marker d2s1271. 
 
 
HERV-H nucleic acid was detected in the serum in 40% of Danish MS patients vs. in 10% of 
controls (Christensen et al, 2003), indicating increased activation of HERV-H in MS patients. 
Additionally, increased antibody titers against HERV-H env protein were found in Danish MS 
patients (Christensen et al, 2003). Furthermore several cytokines utilizing the NF-KB cascade 
(e.g. TNF?, IFN?) activate HERV-H with a concomitant downregulation of ICOS (Ling V et al, 
2001). 
 
Against this background, variation in ICOS genomic region was analysed by sequencing and 
selected polymorphisms were tested for association with MS. We therefore aimed at extending 
our previous results by genotyping 27 SNPs spanning 100 kb across the ICOS gene region with 
respect to MS susceptibility (table 6).  
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SNP Position Gene MAF p-value 
1. rs231770 204,437,398  0,46 0,17 
2. rs16840252 204,439,764  0,13 0,35 
3. rs5742909 204,440,592 150bp proximal of CTLA4 0,08 0,12 
4. rs231775 204,440,959 CTLA4 0,46 0,47 
5. rs3087243 204,447,164 300bp distal of CTLA4 0,32 0,74 
6. rs960792 204,457,495  0,35 0,67 
7. rs231755 204,461,814  0,14 0,3 
8. rs2882974 204,468,309  0,37 0,76 
9. rs10497873 204,470,572  0,15 0,71 
10. rs11571311 204,481,924  0,21 0,82 
11. rs3116505 204,487,426  0,48 0,79 
12. rs11571306* 204,507,337  0,19 0,47 
13. rs11889031* 204,507,639  0,06 0,7 
14. rs4452124* 204,507,942  0,07 0,12 
15. rs11571305* 204,508,371 1.5kb proximal of ICOS 0,18 0,55 
16. rs10932029 204,510,013 ICOS / intron1 0,12 0,74 
17. rs4355090 204,524,627 ICOS /intron1 0,20 0,23 
18. rs4521021 204,524,820 ICOS / intron1 0,32 0,038 
19. rs4270326* 204,529,859 ICOS / intron3 0,08 0,65 
20. ICOSivs4+1070 204,531,932 ICOS / intron4 0,08 0,6 
21. rs10172036 204,532,528 ICOS / intron4 0,39 0,95 
22. rs10183087* 204,532,569 ICOS / 3’ UTR 0,23 0,84 
23. rs4404254* 204,533,531 ICOS / 3’ UTR 0,22 0,75 
24. rs10932037 204,533,591 ICOS / 3’ UTR 0,11 0,69 
25. rs1559931* 204,533,974 ICOS / 3’ UTR 0,22 0,9 
26. rs10199135* 204,536,856 2.3kb distal of ICOS 0,04 0,72 
27. rs3116534* 204,542,014 HERV-H 0,23 0,67 
Table 6. Results  of  the  association  analysis  performed  on  chromosome  2q33.  Asterisk  (*)  
indicates SNPs genotyped only in 186 MS trio families.  
 
 
 
One polymorphism, located in the first intron of the ICOS locus (rs4521021), showed a 
nominally significant trend for association. However when correction for multiple comparisons 
was applied the association was not significant. The LD analysis showed that the weakly 
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associated polymorphism lies in an interblock region, exhibiting low LD with neighbouring 
markers (figure 8). The presence of low LD in the genomic region where SNP rs4521021 lies 
was also confirmed in a recent study performed on celiac disease, IgA deficiency and common 
variable immunodeficiency patients by Haimila and colleagues (2009). Previously Lorentzen 
and colleagues (2005) have analyzed the role of variation in the ICOS gene in Norwegian MS 
patients. No association with the disease was found although the coverage of the region was poor 
(only  two  microsatellites  were  genotyped)  with  subsequent  limited  power.  One  of  the  two  
microsatellites included in the study was also genotyped in 186 Finnish MS trio families but it 
did not show association with the disease. Another study has investigated variations in 3’ UTR 
of the ICOS gene in MS (Castelli et al, 2007). A correlation between a three SNPs haplotype and 
reduced ICOS expression was found. Homozygotes for such haplotype were underrepresented in 
MS patients when compared to controls and exhibited lower expression of ICOS and higher 
levels of circulating interleukin 10. Our study included five SNPs located in the 3’ UTR of ICOS 
(we included also one SNP of the associated three markers haplotype) but no association could 
be detected. A recent GWAS performed in American and British patients did not find an 
association with the ICOS locus although only four SNPs (none of which was included in our 
study) were included (IMSGC, 2007). 
 
Figure 8. LD plot of chromosome 2q33. Darker color denotes higher LD (D’). Filled boxes 
indicates the genes. Numbers refer to the markers shown in Table 6. 
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Due  to  the  close  proximity  of  the  weakly  (non-significantly)  associated  SNP  to  the  exon  2  
boundary, we further characterized the expression of the ICOS gene, searching for possible 
alternative splicing. By reverse transcriptase-polymerase chain reaction (RT-PCR) two different 
isoforms were detected in inactivated and activated human CD4+ T-cells. A full length form of 
ICOS (fl-ICOS) and a splice variant lacking 450 nucleotides were identified (Figure 1B in Study 
IV). Sequence analysis revealed an alternatively spliced variant (?ex2-ICOS) that lacked exon 2 
encoding most of the extracellular domain of fl-ICOS (Figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Schematic showing comparative protein domains of fl-ICOS and ?ex2-ICOS. 
Numbers refer to amino acid positions in the nascent polypeptide. Arrows indicate the potential 
N-linked glycosilation sites. 
 
 
The ?ex2-ICOS is predicted to consist of just 86 residues, including signal sequence, ten amino 
acids of the extracellular domain, transmembrane domain and the cytoplasmatic tail identical to 
fl-ICOS. ?ex2-ICOS lacks thus most of the extracellular domain where the the binding domain 
for its ligand, ICOS-L, lies. It has been showed that upon T-cell stimulation the expression of fl-
ICOS is rapidly induced (Beier et al, 2000). We found that the expression kinetics of ?ex2-ICOS 
was similar to fl-ICOS (Figure 1B in Study IV). We found that when CD4+ T-cells were 
stimulated with PMA and ionomycin, ?ex2-ICOS mRNA levels increased accordingly. 
 
To determine whether ?ex2-ICOS transcript could direct protein production, the expression of 
?ex2-ICOS protein was studied in transfected cells and human-derived cell lines (Figure 2A and 
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2B in Study IV). Our results showed that ?ex2-ICOS protein is expressed in non-activated 
Jurkat cells and that activation with PMA and ionomycin further increases the protein synthesis 
as expected from the RT-PCR experiment. 
 
We made a further effort to study the subcellular localizations of fl-ICOS and ?ex2-ICOS in 
transfected cells (Figure 3A and 3B in Study IV). As expected fl-ICOS was localized mostly at 
the cell membrane whereas ?ex2-ICOS was found to be distributed mainly intracellularly with 
exclusion of the nuclei. Staining of the cells with an endoplasmatic reticulum (ER) marker 
showed that fl-ICOS only partially colocalize with ER with most of the signal distributed at the 
cell membrane. ?ex2-ICOS signal instead overlapped with the organelle marker labeled area, 
with most of the protein accumulated in the perinuclear region of ER. 
 
We have reported a novel, possibly regulatory, transcriptional variant of ICOS. Alternative 
splicing of membrane receptors is a common strategy to increase the repertoire of receptors 
available to the cell. Other immune mediators such as CTLA4 and CD28 have shown a similar 
regulative mechanism. CTLA4 is known to have three splicing variants encoding for different 
proteins, a full length membrane bound (fl-CTLA4), a soluble (sCTLA4) and a ligand 
independent (liCTLA4) (Ueda et al., 2003; Vijayakrishnan et al., 2004). Also CD28 has been 
reported to undergo alternative splicing resulting in two different variants encoding for different 
proteins, a full-length (CD28) and a shorter variant (CD28i), both localized at the cell membrane 
(Hanawa et al, 2002). The mRNA of ?ex2-ICOS lacks exon 2, which encodes for most of the 
extracellular domain of fl-ICOS, essential for interactions with its ligand, ICOS-L. Interestingly, 
both liCTLA4 and CD28i lack exon 2 as well and as a consequence they lack most of the ligand 
binding domain. However, both proteins are able to translocate to the cell surface in mammalian 
cells. Our results show instead that ?ex2-ICOS protein is localized mainly intracellularly, with 
most  of  the  signal  present  in  ER.  The  differential  subcellular  localization  of  ?ex2-ICOS when 
compared to fl-ICOS suggests that ?ex2-ICOS might exert its function mostly in the ER. What 
could be its role in this subcellular compartment is still an open question. It is known that lectins 
(like calreticulin and calnexin) control retention of incorrectly glycosylated or folded proteins in 
the  ER  (Helenius,  1994).  fl-ICOS  bears  two  potential  N-linked  glycosylation  sites,  whereas  
?ex2-ICOS transcript lacks both sites. Loss of these glycosylation sites in ?ex2-ICOS molecule 
might thus promote endoplasmic retention, preventing effective translocation of the receptor to 
the cell membrane. Future experiments are needed to uncover the function of ?ex2-ICOS protein 
and its role in regulation of the overall ICOS expression.  
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2. IRF5 GENE AND MS 
 
Nine SNPs and one pentanucleotide (CGGGG) insertion-deletion in the interferon regulatory 
factor 5 gene (IRF5) were selected for genotyping in three independent MS populations from 
Spain, Sweden and Finland. The markers included in the study were selected because of 
previous association with immune-mediated disorders or for their role in regulating IRF5 
transcriptional levels. Two of the SNPs and the pentanucleotide insertion-deletion polymorphism 
revealed association with MS (Table 7). The two SNPs are located 5 kb upstream of the alternate 
promoter 1A and in the first intron respectively, whereas the pentanucleotide CGGGG is situated 
64 bp upstream the alternate promoter 1A (Figure 9). 
 
POLYMORPHISM SPANISH 
case (N=660) controls 
(N=833) 
p-value 
SWEDISH 
cases (N=1166) 
controls (N=1235) 
p-value 
FINNISH 
trios (n=511) 
p-value 
COMBINED 
p-value 
rs4728142 0.003 0.02 0.035 0.0002 
CGGGG indel 0.005 0.009 0.056 0.0005 
rs3807306 0.004 0.049 0.012 0.0002 
Table 7. SNPs associating with MS in the three different cohorts. 
 
 
IRF5 consists of nine exons with three alternative non-coding 5’ exons named 1A, 1B and 1C 
respectively (Figure 10). The majority of IRF5 transcripts starts with exon 1A which generates 
the most efficient 5’UTR in protein synthesis, whereas mRNA starting with exon 1C has 
inhibitory effect (Kozyrev et al 2007). The expression pattern of IRF5 is complex, involving 
nine at least splicing variants whose functional roles are still not well understood (Mancl et al 
2005). 
 
IRF5 belongs to the family of regulatory factors activated by type I interferon (IFN) pathway, a 
group of proteins involved in the regulation of immune responses (Taniguchi et al 2001). It is 
expressed mainly in dendritic and B-cells and its transcription is further enhanced by the 
activation of the IFN pathway (Mancl et al 2005). IRF5 is a cytoplasmatic protein anchored on 
endosomes by binding with MyD88 where it regulates toll-like receptors (TLR) signalling 
pathway. In the endosomal compartment TLRs 7/8 and 9 represent the internal sentinels of the 
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cell sensing infections (Honda and Taniguchi 2006). Upon activation of TLRs 7/8 and 9, IRF5 is 
phosphorylated and subsequently able to dimerize and translocate to the nucleus where it binds 
IFN-stimulated responsive elements (ISREs), DNA sequences that tune the expression of target 
genes. 
 
 
 
 
 
 
 
 
 
 
Figure 10. Genomic structure of IRF5 gene and polymorphisms included in the study. The 
markers  associated  with  MS are  shown in  bold.  UTR regions  are  indicated  with  empty  boxes,  
coding exons are shown as shaded boxes.  
 
 
IRF5 gene has already been associated with other autoimmune disorders such as SLE, 
rheumatoid arthritis (RA) and inflammatory bowel disorder (IBD) (Sigurdsson et al 2005, 
Sigurdsson et al 2007, Dideberg et al 2007). These studies  suggest that a proximal and a distal 
region play a relevant role in the susceptibility to these diseases (Table 8). 
 
DISEASE BEST ASSOCIATED 
POLYMORHISM 
LOCATION 
IBD CGGGG indel promoter/first intron 
Sjögren’s syndrome rs10488631 5 kb downstream of IRF5 
Sjögren’s syndrome CGGGG indel promoter/first intron 
SLE CGGGG indel promoter/first intron 
SLE rs10954213 3’ UTR 
RA rs3807306 promoter/first intron 
Table 8. Summary of the IRF5 SNPs associated with autoimmune disorders. 
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This scenario is particularly relevant for SLE and Sjögren’s syndrome, where the two gene 
regions are independently associated with the disease (Ferreiro-Neira et al 2007, Nordmark et al 
2009) whereas in IBD, MS and RA the association is detected only from the proximal portion of 
IRF5.  Our  study  is  the  first  to  address  to  the  role  of  IRF5  in  MS  susceptibility.  In  the  three  
independent cohorts from Sweden, Spain and Finland we found association with three markers 
located in the proximal part of the gene. These polymorphisms are in relatively high LD with 
each other and within the power of the analysis we cannot distinguish which one of them would 
be the primarily associated variant (Figure 2 in Study II).  Furthermore the risk alleles were all  
present on the most common haplotype, whose association signal was comparable to the ones 
obtained in the single marker analysis. However, in a study on IBD patients the same three 
markers were associated with the disorder and, due to the effect size of the polymorphisms, it 
was possible to show that the pentanucleotide indel variation was the most significantly 
associated marker (Dideberg et al 2007). 
 
Case-control association studies are affected by problems concerning population stratification, 
resulting in contradictory results among different studies. This lack of reproducibility is often 
attributed to marked variation of disease prevalence and marker allele frequency within 
subpopulations, yielding false evidence for an association (Cardon et al, 2003). Our study avoids 
these pitfalls by analysing the role of IRF5 gene in MS susceptibility in three different Caucasian 
populations. Furthermore the utilization of family-based in addition to case-control materials 
strengthens the results shown here.  
 
In recent years data on genetic regulation of IRF5 has been accumulated (Figure 10). Graham 
and colleagues (2006) have described a functional SNP (rs2004640) that creates a donor splice 
site in the first intron, resulting in the inclusion of the alternative untranslated exon 1B. A second 
polymorphism (rs10954213) that alters the polyadenylation of the gene has been identified as 
modulator of the transcripts half-life (Graham et al 2007). Finally an insertion/deletion located in 
exon 6 encodes for a repetitive sequence in the PEST domain, a proline-rich region presumably 
involved in protein-protein interaction (Kozyrev et al 2007).  
 
Our study has suggested a possible functional role for the polymorphisms associated with MS. 
We used electrophoretic mobility shift assay (EMSA) to test whether the alleles of the three 
variants associating with MS had differential protein binding. We detected stronger protein 
affinities for the risk alleles of the SNP rs4728142 and the indel variation, whereas both alleles 
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of the SNP rs3807306 seem to bind equal amounts of protein extract (Figure 3 in Study II). 
Sequence analysis of the insertion polymorphism revealed an additional binding site for SP1 and 
we further characterized the in silico prediction with the proximity ligation assay, a novel variant 
of  immunoPCR  (Gustafsdottir  et  al  2007).  Indeed  we  were  able  to  show  that  SP1  binds  both  
alleles of the CGGGG repeat and increased amounts of SP1 bind to the risk allele (the 
4xCGGGG allele). Interestingly the proximal region of IRF5 has a high content of CpG islands 
and several binding sites for SP1, two features that are very common in housekeeping genes 
because they ensure high expression. The increased binding affinity for SP1 in the case of the 
CGGGG insertion can drive higher expression of IRF5, with the carriers of the risk variant being 
more susceptible to higher levels of circulating type I IFN. It is worth noting that IRF5-deficient 
mice are vulnerable to viral infections and have a reduced level of type I IFN in their sera (Yanai 
et al 2007). 
 
Ronnblom and co-workers (1991) reported an increased incidence of autoantibodies production 
and autoimmune disorders among cancer patients treated with alpha-interferon, suggesting 
almost  twenty  years  ago  that  type  I  IFN  could  play  a  central  role  in  autoimmune  disorders  
pathogenesis. Recently increasing evidence has been accumulated in SLE, RA and Sjögren’s 
syndrome (Baechler et al 2003, van der Pouw Kraan et al 2007, Bave et al 2005). In MS a 
subgroup of patients is characterized by increased expression of IFN-induced genes (van 
Baarsen et al 2006). Furthermore administration of IFN-? is one of the most common first-line 
strategies used to impact the early course of MS because of the IFN-? antagonizing effects. 
However, IFN-? knockout (KO) mice are more susceptible to EAE compared to their wild-type 
littermates  (Teige  et  al  2003).  They  develop  also  a  more  severe  disease  phenotype  with  more  
extensive CNS inflammation and demyelination. Although compensatory mechanisms induced 
by the lack of IFN-? cannot be ruled out, these findings suggest an important role played by type 
I IFN pathway in the pathogenesis of autoimmune disorders. 
 
 
 
 
 
 
 
 
 
65
3. CHROMOSOME 19q13 AND MS  
 
Sixteen markers located in the chromosomal region 19q13 were tested in 459 MS trio families 
for allelic association using the transmission disequilibrium test (TDT) (Figure 11); nominally 
significant associations were tested in an independent cohort of 323 families as well as in the 
pooled dataset of 782 families. No statistically significant association with MS was found. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Genomic location of the marker included in chromosome 19q13 study. 
 
 
Chromosome 19q13 is one of those genomic regions that have has repeatedly provided linkage or 
association signals in MS although there is lack of replication in the published studies and no clear 
signal emerging from the region (Table 9). The results from linkage screens appear to be more 
consistent when compared to the association studies, although the statistical significance of most of 
the analyses is only modest (Table 9). Nevertheless, Wise et al (1999) have identified this 
chromosomal area as one of the most interesting non-HLA loci in a meta-analysis of linkage 
screens.
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Table 9.  Previous studied on the role of chromosome 19q13 in MS susceptibility. 
 
Reference Type of study Best marker/subregion Country Subjects Significance 
Sawcer et al., 1996 Linkage d19s246/19q13.4 UK 227 multiplex families                 LOD=1 
Haines et a., 1996 Linkage d19s219/19q13.2 USA 52 multiplex families LOD=1.13 
Ebers et al., 1996 Linkage d19s47/19q13.2 Canada 100 sibling pairs LOD=0.73 
Kuokkanen et al., 1997 Linkage d19s246/19q13.4 Finland 16 multiples families LOD=1 
D´Alfonso et al., 1999 Linkage 19q13.3 Italy 69 families LOD<0.7 
Coraddu et al., 2001 Linkage 19q13 Italy/Sardinia 49 multiplex families LOD<0.7 
Broadley et a., 2001 Linkage 19q13 Italy 40 multiplex families LOD<0.7 
Green et al., 2001 Linkage CEA/19q13.2 USA 161 multiplex LOD=1.25 
Xu et al., 2001 Linkage D19S246/19q13.4 Sweden 46 multiplex families NPL score -0.46 
Reunanen et al., 2002 Linkage d19s1175/19q13.1 Finland 27 multiplex families LOD=1.8 (DR15-) 
Haines et al., 2002 Linkage d19s879/19q13.4 USA 98 multiplex families LOD=3.01 
Lucotte et al., 2002 Linkage 19q13.3 France 18 multiplex families LOD=2.1 
Pericak-Vance et al. 2004 Linkage D19S217/19q13.2 USA 98 multiplex families LOD=2.17 
Pericak-Vance et al. 2004 Linkage D19S217/19q13.2 USA 53 families, HLA-DR15+ LOD=2.37 
Pericak-Vance et al. 2004 Linkage D19S217/19q13.2 France 90 families LOD<0.7 
Haghighi et al., 2006 Linkage with OCBa D2S219/19q13.2 Sweden 2 extended families LOD=1.8 
Schmidt et al., 2002 Association APOE ?2-haplotype USA 328 families p=0.005 
Yeo et al., 2003 Association d19s585/19q13.4 UK 961 patients p=0.12 
Ban et al., 2003 Association d19s219/19q13.2 Australia 217 patients p=0.009 
Koch et al., 2005 Association ILT6/ 19q13.4 Germany, France 751 patients p=0.009 
Burwick RM et al., 2006 Association APOE/19q13.2 meta-analysis 3200 patients p>0.05 
Burton et al., 2007 Association ZNF45 and GIPR/19q13.2 UK 1000 patients p=0.00005 and p=0.0008 
Hafler et al., 2007 Associationb MAG, CD22, TYROBP/19q13.1c UK, USA 931 trios/2431 controls p>0.05 
Hafler et al., 2007 Associationb APOE, ZNF45, GIPR/19q13.2c UK, USA 931 trios/2431 controls p>0.05 
Hafler et al., 2007 Associationb synaptogyrin4/13q13.3d UK, USA 931 trios/2431 controls p=0.02/0.0003 
Hafler et al., 2007 Associationb ZNF577/19q13.4d UK, USA 931 trios/2431 controls p=0.04/0.001 
a OCB= oligoclonal bands in cerebrospinal fluid. 
b We search for association on chromosome 19q13 between positions 40Mb and 60Mb for the following criteria: TDT statistics have a p-value<0.05 or CMH statistics have a 
p-value<0.001 (https://imsgc.org/php/results.php). 
c The 19q13.1 region  harbouring MAG, CD22, TYROBP (40-42 Mb) and the 19q13.2 region harbouring APOE, ZNF45 AND GIPR (49-51 Mb) were analysed with 128 and 
177 markers, respectively, all of which failed to show any association (in both TDT and CMH statistics). 
d These markers fulfilled the association criteria. 
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Koch and colleagues (2005) reported increased frequency of ILT6 deficiency in German MS 
patients compared to healthy controls (7.1% vs. 3.8%). The gene maps to the leukocyte receptor 
complex on 19q13.4, a genomic region which encodes for several immunological receptor proteins. 
We tested the role of ILT6 deficiency in Finnish MS patients with TDT and case-control settings. In 
the family-based approach we could not detect any transmission distortion for the null allele and the 
frequency of the null genotype was only slightly increased in MS cases (14% vs. 11.6%), revealing 
no statistically significant association between ILT6 deficiency and MS susceptibility. Recently 
Ordoñez et al (2009) have analyzed whether ILT6 deletion associated with Spanish MS patients in a 
case-control study. ILT6 deficiency in at least one chromosome was more common for MS cases 
(p-value = 0.006) although the increase of null-allele homozygotes was only marginally significant 
and not replicated in another independent dataset, questioning the primary role of ILT6 in MS 
predisposition.  
 
Located in 19q13.2 subregion, APOE has been the object of several studies using both linkage and 
allelic association approaches with conflicting results (Table 9). Already identified as a genomic 
region harbouring a putative predisposing MS gene in several screens (Multiple Sclerosis Genetic 
Group 1996, Sawcer et al 1996, Ebers et al 1996, Kuokkanen et al 1997), this area of chromosome 
19 has been the focus of extensive research. A study combining linkage and association analysis in 
98 families (Pericak-Vance et al 2001) suggested that a locus near APOE could affect the risk of 
developing MS; furthermore a HLA stratification analysis indicated that most of the positive LOD 
scores arose from DR-2 positive families. In an attempt to investigate a number of potentially 
interesting genomic regions with a linkage study, Pericak-Vance et al (2004) also tested subregion 
19q13.2 in 98 American and 90 French multiplex families. Although no significant association with 
MS was found, stratification analysis revealed a maximum LOD of 1.07 in DR-15 negative families 
with a marker located in the vicinity of APOE locus. In a case-control study a marginal association 
of  allele  ?4  of  APOE  with  protection  to  MS  was  found  in  a  cohort  of  Chinese  MS  patients  
(Barcellos et al 1997). The functional APOE polymorphisms (alleles ?2, ?3 and ?4) and other SNPs 
in close vicinity were tested in a family-based association analysis (Schmidt et 2002). Single-
marker analysis did not show any significant association whereas a four-marker haplotype including 
allele ?2 was associated with MS. When disease progression was included, the analysis showed that 
MS patients carrying allele ?4 are more likely to develop a severe clinical course. In a meta-analysis 
of 3200 MS cases and 2500 controls and 1200 family-based material, Burwick and colleagues 
(2006) were not able to detect any significant association of APOE epsilon allelic and genotypic 
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variation with MS susceptibility. Furthermore in a pooled analysis of over 4000 MS patients no 
evidence for an APOE epsilon influence on disease severity was found.  
In our study we have genotyped three markers located near or within the gene locus and performed 
a single marker as well three-points haplotype analyses. We found a negative association with the -
219T/+113C/?3 haplotype which was underrepresented in MS patients with p=0.007. Curiously, 
this APOE haplotype has been showed to protect against Alzheimer disease in Finnish population 
(Myllykangas et al 2002). When tested in another independent dataset the initial association was not 
replicated as well as when association was analyzed in the two pooled datasets. Using the total 
cohort of MS patients in our possession, APOE haplotype analysis was performed also in a case-
control  setting  but,  again,  no  association  was  detected.  Using  the  dataset-1  with  459  MS  trio  
families we have approximately 80% power to detect a dominant predisposing variant with an odds 
ratio of 1.5 (marker and disease allele frequencies set to 0.20, D' value 1.0).With lower disease 
allele  frequencies  the  power  decreases.  We  concluded  that,  given  the  power  of  our  study,  allelic  
variation in APOE is unlikely to have a major role in genetic susceptibility to MS.  
 
The other marker that showed initially negative association with MS in our study was D19S876, a 
microsatellite located in 19q13.1 subregion; when tested in a second independent dataset the allelic 
association with the microsatellite was not replicated. When the two datasets were pooled, p-value 
reached borderline nominal significance but it cannot be regarded as statistically significant since 
multiple comparisons were made. The same marker has been previously associated in continental 
Italian patients although the associated allele was different than in our study (D’Alfonso et al 2000). 
From these results we can conclude that the effect of the disease gene in LD with D19S876 might 
be modest and hence larger studies are needed to determine whether allelic variation in this 
genomic area significantly associates with MS.  
 
In a previous study, Reunanen and co-workers (2002) obtained a LOD score of 1.8 in DR15-
negative multiplex families peaking with D19S1175, a microsatellite located as well in the 19q13.1 
subregion. In our dataset we could not find any statically significant association neither with 
D19S1175 nor with two candidate genes located in the close proximity, TYROBP and DAP10. 
TYROBP is of some interest since mutations in this locus are known to cause polycystic 
lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL) disease, a 
multisystemic degenerative disorder characterized by demyelination of white matter. We also 
sequenced both genes in the proband of the multiplex family that mostly contributed to the LOD 
score but we could not detect any insertion/deletion or non-synonymous amino acid changes. Three 
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SNPs were found in the proximal end of TYROBP gene and two were included in the study but 
none of them revealed association with MS. These results have been strengthened in a recent study 
by Sulonen et al (2009) which revealed no association between TYROBP mutations implicated in 
PLOSL and MS in a linkage and association study. 
 
The failure of identifying MS-associated variants highlights the limits of an indirect approach such 
as  the  allelic  association  study  when  common  variants  are  not  involved  in  the  susceptibility  of  
complex disorders. In the case of a more complex scenario where genetic and locus heterogeneity 
play a role then linkage studies still remain the best option. With the recent progress of technologies 
more direct tools like large-scale sequencing are becoming readily available and could complement 
linkage and association studies. 
 
The previous linkage study in the DR15-negative multiplex families revealed a relatively sharp 
peak with D19S1175 marker (Reunanen et al 2002). Linkage analysis suggest recombination 
between the putative predisposing gene and markers D19S425 and D19S610, defining a candidate 
region of just 850 kb. This genomic area includes 48 genes of which some are of relevant interest in 
the context of MS. Two of the most obvious candidate genes that might be involved in disease 
susceptibility, myelin associated glycoprotein (MAG) and ?-crystallin-related B6 (HSPB6), have 
been sequenced in families that mostly contributed to the LOD score, but no obvious mutations in 
exons were found (unpublished). Nevertheless this genomic region harbours other interesting 
candidate genes and a re-sequencing-based approach in selected patients might reveal new insights 
for the role of the 19q13.1 subregion in MS predisposition. 
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CONCLUSIONS AND FUTURE PROSPECTS 
 
The work presented in this thesis has lead to the identification of IRF5 as new MS susceptibility 
gene and has uncovered the presence of an alternative variant of ICOS, a member of co-stimulatory 
receptors on the surface of T-cells. Moreover the role of chromosomal region 19q13 in MS 
predisposition has been further analysed.  
 
IRF5 gene has been already shown to be associated with other inflammatory or autoimmune 
disorders such as SLE, RA and IBD. We found evidence for a role of a common IRF5 allele in MS 
susceptibility in analyses of three different populations. Three polymorphisms reached nominal 
significance for association with the disease and one of the risk alleles was functionally 
characterized, showing increased binding affinity for the transcriptional factor SP1. The findings 
presented here add to the evidence that there might be genes or pathways that are common between 
multiple immune-mediated diseases, and that type I IFN signalling, in which IRF5 participates, is 
possibly one of these pathways. However, future studies are required to unequivocally identify the 
causative variants and to uncover the intricate expression profile of IRF5 in MS patients. 
 
The genomic scan for the role of chromosome 2q33 in MS predisposition excluded the candidacy of 
CTLA4, revealing a trend for association around ICOS gene. Although not statistically significant 
upon correction for multiple comparisons, the association signal suggests the need for a more 
thorough analysis of this locus and its involvement in MS pathogenesis. Focused analyses on 
geographical clusters with founder effect such as the Southern Ostrobothnian isolate, would 
minimize genetic and environmental heterogeneity and be informative in elucidating the role of this 
chromosomal region in MS susceptibility.  
 
The work presented here open new views on a more general immunological process such as the co-
stimulatory pathway of immune responses and also expanded the knowledge about the expression 
of the ICOS gene. We discovered and further characterized a novel transcript isoform named ?ex2-
ICOS. The stability of the translated protein and its subcellular localization were investigated. This 
finding underlines the importance of alternative splicing as regulator of immunological processes. 
The differential subcellular localization of ?ex2-ICOS when compared to the full-length protein 
raises questions about the function of such protein in the co-stimulatory pathway. Future studies are 
needed to unravel the importance of this isoform in ICOS regulation. A better understanding of the 
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functional role of ?ex2-ICOS with respect to the subcellular environment and different T-cell 
subpopulations might shed more light on the mechanism underlying ICOS regulation. 
 
Here we present also a follow-up analysis on chromosome 19q13 and MS. Although suggestive 
evidence for linkage had been reported in several studies, we were not able to detect any allelic 
association with MS. However a trend for association in subregion 19q13.1 might warrant further 
future investigation to dissect the role of allelic variation in our patients material. This analysis 
suggests that approaches based on linkage disequilibrium (allelic association) between marker 
alleles and MS susceptibility alleles may not be the method of choice to unravel predisposing genes 
risk alleles on this genomic region in case of genetic heterogeneity or variants with small risk. The 
putative susceptibility locus on this genomic area remains still elusive, suggesting a scenario that is 
more complex than previously assumed. Recently we have observed a shift in the field of complex 
genetics which is moving from LD-mapping of disease loci at population level to sequencing 
genomic DNA at individual level. The findings from GWASs to date have explained only a small 
fraction of the heritability for common diseases. This suggests that there are other genetic factors 
contributing to complex disorders but not yet discovered that are simply not detectable by this 
indirect approach. Nevertheless the use of high-throughput sequencing might also help to pinpoint 
disease genes in the associated loci found by case-control or family-based studies. Allelic and even 
locus heterogeneity within 19q13 might render the search for the causative variants quite 
demanding: a more direct, sequencing-based approach may be needed to solve the role of this 
genomic region in MS. The linkage analysis has suggested a possible role for a chromosomal area 
of approximately 850 kb that includes 48 genes. Some of the best candidate loci have been already 
sequenced in selected individuals with no obvious mutations detected in the coding region. Further 
sequence analysis might uncover allelic variation involved in MS genetic susceptibility. 
 
Despite intense research we still do not have a clear knowledge about the pathogenic mechanisms 
underlying MS. Rather than a homogeneous and unitary disorder, MS is a phenotypically 
heterogeneous disease, representing most likely an overlapping spectrum of related conditions, such 
as opticospinal MS, PPMS and RRMS. This heterogeneity probably reflects different molecular 
backgrounds only partially shared among different forms of MS that in turn masks possible 
association signals. A more documented classification of the MS patients in future might help to 
develop more targeted approaches for deciphering the genetic bases of this disease. 
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The  complex  nature  of  the  disease  with  several  genes  involved,  each  adding  a  small  risk  to  the  
predisposition, has proven to be difficult to unravel. Nevertheless the results presented in this thesis 
work help to improve the understanding of the molecular background of this disorder. A better 
knowledge of disease pathogenesis could translate into targeted preventive strategies and possible 
future therapies.  
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